Effects of an urban sanitation intervention on childhood enteric infection and diarrhea in Maputo, Mozambique: A controlled before-and-after trial

  1. Jackie Knee
  2. Trent Sumner
  3. Zaida Adriano
  4. Claire Anderson
  5. Farran Bush
  6. Drew Capone
  7. Veronica Casmo
  8. David Holcomb
  9. Pete Kolsky
  10. Amy MacDougall
  11. Evgeniya Molotkova
  12. Judite Monteiro Braga
  13. Celina Russo
  14. Wolf Peter Schmidt
  15. Jill Stewart
  16. Winnie Zambrana
  17. Valentina Zuin
  18. Rassul Nalá
  19. Oliver Cumming
  20. Joe Brown  Is a corresponding author
  1. London School of Hygiene & Tropical Medicine, Faculty of Infectious Tropical Diseases, Disease Control Department, United Kingdom
  2. Georgia Institute of Technology, School of Civil and Environmental Engineering, United States
  3. WE Consult ltd, Mozambique
  4. Georgia Institute of Technology, School of Chemical and Biomolecular Engineering, United States
  5. University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, United States
  6. Instituto Nacional de Saúde, Mozambique
  7. University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Environmental Sciences and Engineering, United States
  8. London School of Hygiene & Tropical Medicine, Faculty of Epidemiology and Population Health, Department of Medical Statistics, United Kingdom
  9. Georgia Institute of Technology, School of Biological Sciences, United States
  10. Yale-NUS College, Division of Social Science, Singapore

Abstract

We conducted a controlled before-and-after trial to evaluate the impact of an onsite urban sanitation intervention on the prevalence of enteric infection, soil transmitted helminth re-infection, and diarrhea among children in Maputo, Mozambique. A non-governmental organization replaced existing poor-quality latrines with pour-flush toilets with septic tanks serving household clusters. We enrolled children aged 1–48 months at baseline and measured outcomes before and 12 and 24 months after the intervention, with concurrent measurement among children in a comparable control arm. Despite nearly exclusive use, we found no evidence that intervention affected the prevalence of any measured outcome after 12 or 24 months of exposure. Among children born into study sites after intervention, we observed a reduced prevalence of Trichuris and Shigella infection relative to the same age group at baseline (<2 years old). Protection from birth may be important to reduce exposure to and infection with enteric pathogens in this setting.

Introduction

Rapid urbanization has led to the expansion of informal settlements in many low- and middle-income countries (LMICs). Such settlements often have very limited sanitation infrastructure (UN-Habitat, 2016). Separation of human waste from human contact can prevent exposure to enteric pathogens that cause infection, diarrhea (Liu et al., 2016), and potentially long-term health effects such as environmental enteric dysfunction (EED) (Kosek and MAL-ED Network Investigators, 2017), linear growth deficits (Rogawski et al., 2018), impaired cognitive development (MAL-ED Network Investigators, 2018), and reduced oral vaccine immunogenicity (Parker et al., 2018). Children living in densely populated slum areas where fecal contamination is pervasive and sanitation infrastructure is limited may be at an increased risk of adverse health effects due to frequent exposure to enteric pathogens (Ezeh et al., 2017; Fink et al., 2014).

Household-level sewerage has demonstrated health benefits (Barreto et al., 2010; Barreto et al., 2007; Norman et al., 2010) and remains an important long-term goal for many urban settings despite limited evidence from controlled trials (Norman et al., 2010; Wolf et al., 2018). Such systems may not be feasible short-term solutions due to cost, space, and logistical constraints, challenges that have also impeded their evaluation via randomized trials (Norman et al., 2010). Further, in densely populated areas, there may not be space for household-level sanitation of any type. Shared sanitation is a subject of considerable debate but may represent the only near-term sanitation option in some settings (Evans et al., 2017; Heijnen et al., 2014; Tidwell et al., 2020). Yet, while shared, onsite systems may fill the growing need for safe sanitation in rapidly expanding urban areas in LMICs, to date, there has been little evidence of their health impacts in these settings. Recent large-scale, rigorous evaluations of onsite sanitation interventions and combined water, sanitation, and hygiene (WASH) interventions have demonstrated mixed effects on health (Clasen et al., 2014; Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial Team et al., 2019; Luby et al., 2018; Null et al., 2018; Patil et al., 2014; Pickering et al., 2015) but all were conducted in rural areas with household-level interventions, and their findings may have limited generalizability to urban areas. A recent meta-analysis estimated that non-sewered interventions reduced the risk of self-reported diarrhea by 16% but did not estimate effects on objective health outcomes, such as enteric infection (Brown and Cumming, 2020), and could not stratify estimates by rural versus urban setting given the lack of evidence in urban areas (Wolf et al., 2018). To date, no controlled trials of urban onsite sanitation have been conducted despite over 740 million urban residents relying on such technologies (Berendes et al., 2017).

The Maputo Sanitation (MapSan) trial was the first controlled trial to evaluate an onsite, shared sanitation intervention in an urban setting and the first to use the prevalence of enteric infection, as detected by molecular methods, as the primary study outcome (Brown et al., 2015). The study was located in densely populated, low-income, informal neighborhoods of Maputo, Mozambique where the sanitary conditions are poor and disease burden high (Knee et al., 2018). As of 2017, only half of urban residents in Mozambique had access to at least basic sanitation infrastructure, 3% had access to sewerage, and 9% shared sanitation with multiple households, often in poor neighborhoods where space and resources are limited (UNICEF/WHO, 2019). We investigated whether an engineered, onsite, shared sanitation intervention could reduce enteric infection and diarrhea in young children living in these low-income, densely populated neighborhoods in Maputo, Mozambique.

Results

The MapSan trial was a controlled before-and-after (CBA) trial designed to evaluate the impact of an onsite sanitation intervention on child health after 12 and 24 months of follow-up. The intervention consisted of pour-flush toilets to septic tanks with soakaway pits to discharge the liquid portion of the waste. A non-governmental organization (NGO) delivered the intervention to clusters of households known as compounds, replacing the existing poor-condition shared facilities. Control compounds did not receive the intervention and continued to use their poor-condition sanitation for the duration of the study. We assessed several measures of child health, including enteric infection measured via stool-based molecular methods, soil-transmitted helminth (STH) re-infection measured via Kato-Katz, and diarrhea measured via caregiver report in both intervention and control children during three phases: baseline (pre-intervention), 12-month follow-up, and 24-month follow-up. Children were eligible for baseline enrollment if they were less than 4 years old (1–48 months old). At follow-up, children were eligible for enrollment if they were less than 4 years old or if they would have been less than 4 years old during baseline.

We enrolled 987 children in 495 compounds during the baseline phase (February 2015 – February 2016) and collected stool samples (whole stool or diaper samples containing liquid diarrhea) from 765 children (78%) (Figure 1). During the 12-month follow-up phase (March 2016 – April 2017), we enrolled or revisited 939 children in 438 compounds and collected 805 stool samples (86%). During the 24-month follow-up phase (April 2017 – August 2018), we enrolled or revisited 1001 children in 408 compounds and collected stool samples from 922 (90%). To improve the success rate of stool sample collection during the 12- and 24-month follow-up visits, we collected rectal swabs from children who did not provide a whole stool sample after multiple collection attempts. The proportion of each type of sample (whole stool, diaper sample, and rectal swab) was similar between arms at each phase (Appendix 1—figure 1). Fewer than 5% of all samples were diapers and approximately 7% of 12-month samples and 25% of 24-month samples were rectal swabs (Appendix 1—table 1). The NGO delivered interventions to 15 control compounds after baseline and children in those compounds were censored at the time of intervention receipt (Figure 1). Children living in control compounds that independently upgraded their latrines were included in the main analyses. However, as inclusion of these control children may have diluted the intervention effect, they were excluded from sensitivity analyses designed to understand the impact of the intervention when compared with controls served by poor-condition sanitation throughout the study. Children in intervention and control compounds were enrolled at similar rates during each phase (Appendix 1—figure 2). Due to migration out of the compound, we collected longitudinal data from 62% of children (59% controls, 67% interventions) between baseline and 12-month and 51% of children (46% controls, 58% interventions) between baseline and 24-month.

Trial profile.

*Eligible for enrollment at baseline and/or 12 months but traveling at time of visit. †Children removed from 24-month analysis because their compound received an intervention after completion of the baseline phase. Source files available in Figure 1—source data 1 and Figure 1—source code 1.

At baseline enrollment, intervention compounds had more residents, households, and on-premise water taps than controls, though the number of shared latrines was similar (Table 1). Animals were observed in over half of all compounds. Intervention and control households had similar wealth scores, though intervention households had more members and were more crowded while control households more often had walls made of sturdy materials. All households used a municipal water tap as their primary drinking water source with 78% reporting use of a tap on the compound grounds. At baseline, latrines used by intervention households more often had pedestals or slabs, drop-hole covers, and sturdy walls compared with controls. Consistent with previous estimates in urban Maputo (Satterthwaite et al., 2019), open defecation was rare in our study population with only one control household reporting open defecation at baseline. Baseline characteristics of intervention and control children were similar: the average age at enrollment was 23 months (SD = 13), 51% were female, and 32% were still breastfeeding (Table 1). The age distributions of intervention and control children were similar at baseline and both follow-up phases (Appendix 1—figure 3).

Table 1
Baseline characteristics of enrolled children, households, and compounds.
ControlIntervention
Nn (%) or mean (SD)Nn (%) or mean (SD)
Child level variables
Age at survey, days*520700 (405)441694 (403)
Sex, female520266 (51%)444227 (51%)
Child is breastfed with or without complementary feeding526169 (32%)448143 (32%)
Child is exclusively breastfed52649 (9.3%)44837 (8.3%)
Child feces reported to be disposed of in a latrine526148 (28%)448141 (31%)
Child wears diapers526342 (65%)447294 (66%)
Caregiver completed primary school528287 (54%)451239 (53%)
Child's mother is alive513503 (98%)435426 (98%)
Respondent is child's mother519368 (71%)443284 (64%)
Household level variables
Household population4415.4 (2.4)3656.1 (3.0)
Household wealth score, 0 (poorer) - 1 (wealthier)4400.45 (0.10)3650.44 (0.10)
Household crowding, >3 persons/room44054 (12%)36560 (17%)
Household floor is covered440426 (97%)365333 (91%)
Household wall made of bricks, concrete, or similar440304 (69%)365215 (59%)
Household drinking water source inside compound435324 (74%)360294 (82%)
Latrine used by household has a ceramic or masonry pedestal432153 (35%)359142 (40%)
Latrine used by household has a drop-hole cover434232 (53%)359224 (62%)
Compound level variables
Number of compound members28714 (6.2)20819 (12)
Number of households2873.8 (2.1)2084.4 (3.7)
Number of water taps in compound2830.98 (0.95)2071.4 (1.6)
Number of latrines in compound2871.0 (0.20)2071.1 (0.57)
Number of people sharing a latrine28514 (6.2)19717 (8.9)
Number of households sharing a latrine2853.7 (1.8)1974.0 (2.8)
Latrine walls made of brick, concrete or similar28272 (26%)20467 (33%)
Compound population density, persons/square meter§2810.071 (0.04)2050.087 (0.05)
Compound has electricity that normally functions287251 (87%)208189 (91%)
Compound is prone to flooding287184 (64%)208120 (58%)
Any animals observed in compound287170 (59%)208132 (63%)
Dog(s) observed28714 (4.9%)20814 (6.7%)
Chicken(s) or duck(s) observed28740 (14%)20830 (14%)
Cat(s) observed287149 (52%)208116 (56%)
  1. Data are n (%) or mean (standard deviation) and collected by questionnaire unless otherwise noted.

    * Age range 32–1819 days, IQR 339–1021 days. Age distributions available in Appendix 1—figure 3.

  2. Assessed using Simple Poverty Scorecard for Mozambique (http://www.simplepovertyscorecard.com/MOZ_2008_ENG.pdf).

    Data collected by direct observation.

  3. §Calculated as # of people living in the compound divided by the area of the compound in square meters. Source files available in Table 1—source data 1 and Table 1—source code 1.

We used the Luminex Gastrointestinal Pathogen Panel (GPP), a qualitative multiplex molecular assay, to simultaneously test for 15 enteric pathogens in stool samples, including nine bacteria, three protozoa, and three viruses. We detected ≥1 bacterial or protozoan enteric infection, our pre-defined primary outcome, in 78% (591/753) of children with stools available at baseline. We measured our pre-defined secondary outcome, ≥1 STH re-infection, using the Kato-Katz microscope method and detected ≥1 STH in 45% (308/698) of stools at baseline. The prevalences of pre-defined outcomes, individual pathogens, and pathogen types were similar between the intervention and control arms at baseline (Table 2). The prevalence of most bacterial, protozoan, and STH infections increased with age while the prevalence of enteric viruses decreased with age (Appendix 1—table 2 and Appendix 1—figure 4).

Table 2
Effect of the intervention on bacterial, protozoan, viral, and STH infection and diarrhea at 12 and 24 months post-intervention.
Prevalence12-month Prevalence ratio (95% CI), p-value *24-month Prevalence ratio (95% CI), p-value
Baseline12 month24 monthUnadjustedAdjusted§UnadjustedAdjusted§
Any bacterial or protozoan infection‡
Control313/392 (80%)334/395 (85%)403/459 (88%)........
Intervention278/361 (77%)347/408 (85%)392/462 (85%)1.04 (0.94–1.15), p=0.411.04 (0.94–1.15), p=0.411.00 (0.91–1.10), p=1.00.99 (0.91–1.09), p=0.89
Any STH infection‡
Control170/360 (47%)143/283 (51%)142/253 (56%)........
Intervention138/329 (42%)150/305 (49%)136/292 (47%)1.12 (0.89–1.40), p=0.331.11 (0.89–1.38), p=0.350.94 (0.75–1.17), p=0.590.95 (0.77–1.17), p=0.62
Diarrhea‡
Control67/526 (13%)40/430 (9.3%)53/390 (14%)........
Intervention59/448 (13%)59/436 (14%)53/410 (13%)1.41 (0.80–2.48), p=0.241.69 (0.89–3.21), p=0.110.92 (0.55–1.54), p=0.760.84 (0.47–1.51), p=0.56
Any bacteria
Control271/392 (69%)285/395 (72%)345/459 (75%)........
Intervention227/361 (63%)292/408 (72%)324/462 (70%)1.09 (0.95–1.25), p=0.251.09 (0.95–1.26), p=0.201.03 (0.90–1.18), p=0.691.00 (0.87–1.15), p=0.96
Shigella
Control179/392 (46%)204/395 (52%)269/459 (59%)........
Intervention152/361 (42%)218/408 (53%)245/462 (53%)1.13 (0.91–1.39), p=0.281.12 (0.92–1.38), p=0.270.98 (0.80–1.20), p=0.860.95 (0.79–1.16), p=0.64
ETEC
Control116/392 (30%)142/395 (36%)127/459 (28%)........
Intervention110/361 (30%)143/408 (35%)126/462 (27%)0.93 (0.68–1.28), p=0.660.96 (0.69–1.33), p=0.810.95 (0.67–1.35), p=0.770.83 (0.57–1.19), p=0.31
Campylobacter
Control39/392 (9.9%)32/395 (8.1%)48/459 (10%)........
Intervention21/361 (5.8%)35/408 (8.6%)34/462 (7.4%)1.78 (0.89–3.56), p=0.101.68 (0.82–3.45), p=0.161.20 (0.60–2.39), p=0.601.28 (0.62–2.62), 0.50
C. difficile
Control22/392 (5.6%)13/395 (3.3%)13/459 (2.8%)........
Intervention13/361 (3.6%)17/408 (4.2%)11/462 (2.4%)1.95 (0.71–5.35), p=0.202.09 (0.77–5.64), p=0.151.32 (0.47–3.73), p=0.601.41 (0.46–4.30), p=0.54
E. coli O157
Control13/392 (3.3%)19/395 (4.8%)25/459 (5.5%)........
Intervention18/361 (5.0%)14/408 (3.4%)16/462 (3.5%)0.48 (0.18–1.27), p=0.140.46 (0.18–1.21), p=0.120.43 (0.15–1.29), p=0.130.52 (0.17–1.59), p=0.25
STEC
Control3/392 (0.77%)9/395 (2.3%)17/459 (3.7%)........
Intervention10/361 (2.8%)5/408 (1.2%)15/462 (3.3%)0.14 (0.03–0.67), p=0.0140.15 (0.03–0.70), p=0.0160.23 (0.05–1.03), p=0.0550.24 (0.05–1.01), p=0.052
Any protozoa
Control205/392 (52%)236/395 (60%)303/459 (66%)........
Intervention195/361 (54%)259/408 (63%)296/462 (64%)1.04 (0.87–1.24), p=0.691.03 (0.86–1.22), p=0.760.93 (0.78–1.11), p=0.400.91 (0.76–1.09), p=0.29
Giardia
Control201/392 (51%)230/395 (58%)294/459 (64%)........
Intervention186/361 (52%)251/408 (62%)289/462 (63%)1.06 (0.88–1.27), p=0.551.05 (0.88–1.25), p=0.580.96 (0.80–1.14), p=0.610.93 (0.78–1.11), p=0.44
Cryptosporidium
Control8/392 (2%)8/395 (2%)14/459 (3.0%)........
Intervention16/361 (4.4%)15/408 (3.7%)15/462 (3.3%)0.89 (0.23–3.43), p=0.870.89 (0.24–3.31), p=0.860.46 (0.11–1.93), p=0.290.53 (0.13–2.14), p=0.37
Any virus
Control53/392 (14%)52/395 (13%)59/459 (13%)........
Intervention52/361 (14%)45/408 (11%)62/462 (13%)0.77 (0.45–1.32), p=0.350.75 (0.44–1.27), p=0.290.96 (0.55–1.68), p=0.881.03 (0.57–1.86), p=0.92
Norovirus GI/GII
Control38/392 (9.7%)44/395 (11%)47/459 (10%)........
Intervention39/361 (11%)37/408 (9.1%)55/462 (12%)0.71 (0.38–1.33), p=0.280.68 (0.36–1.27), p=0.231.00 (0.52–1.93), p=0.991.10 (0.55–2.18), p=0.79
Adenovirus 40/41
Control13/392 (3.3%)9/395 (2.3%)7/459 (1.5%)........
Intervention9/361 (2.5%)9/408 (2.2%)6/462 (1.3%)1.34 (0.34–5.23), p=0.681.24 (0.32–4.83), p=0.761.18 (0.23–5.98), p=0.840.97 (0.18–5.19), p=0.97
Coinfection, ≥2 GPP pathogens
Control206/392 (53%)237/395 (60%)302/459 (66%)........
Intervention185/361 (51%)257/408 (63%)282/462 (61%)1.08 (0.90–1.29), p=0.391.08 (0.91–1.29), p=0.370.95 (0.80–1.12), p=0.540.93 (0.79–1.10), p=0.41
Trichuris
Control139/360 (39%)116/283 (41%)124/253 (49%)........
Intervention117/329 (36%)120/305 (39%)117/292 (40%)1.05 (0.82–1.35), p=0.681.01 (0.79–1.28), p=0.960.89 (0.69–1.16), p=0.400.86 (0.67–1.10), p=0.22
Ascaris
Control95/360 (26%)82/283 (29%)78/253 (31%)........
Intervention68/329 (21%)87/305 (29%)56/292 (19%)1.26 (0.87–1.82), p=0.221.33 (0.92–1.93), p=0.130.80 (0.52–1.21), p=290.83 (0.54–1.27), p=0.39
Coinfection, ≥2 STH
Control64/360 (18%)55/283 (19%)60/253 (24%)........
Intervention47/329 (14%)57/305 (19%)37/292 (13%)1.16 (0.76–1.77), p=0.501.17 (0.76–1.79), p=0.490.67 (0.40–1.13), p=0.130.63 (0.37–1.07), p=0.084
  1. Prevalence results are presented as (n/N (%)). All effect estimates are presented as prevalence ratios (ratio of ratios) and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors.

    *Analysis includes all children measured at baseline and 12-month visits.

  2. Analysis includes all children measured at baseline and 24 month visits.

    ‡Outcome was pre-specified in trial registration. All other outcomes are exploratory.

  3. §Pathogen outcomes adjusted for child age and sex, caregiver’s education, and household wealth index. Reported diarrhea was also adjusted for baseline presence of a drop-hole cover and reported use of a tap on compound grounds as primary drinking water source. Sample sizes for adjusted analyses are slightly smaller than numbers presented in prevalence estimates due to missing covariate data. Y. enterocolitica, V. cholerae, E. histolytica, and rotavirus were detected in <2% of samples in each arm at each phase. Descriptive data for these pathogens are available in the Appendix 1—table 2. Source files available in Table 2—source data 1 and Table 2—source code 1.

The characteristics of children with repeated observations (including baseline) were similar to characteristics of children measured at baseline only (Appendix 1—table 3 and Appendix 1—table 4) and to characteristics of children measured at 12 month and/or 24 month only with the exception of age-related characteristics (Appendix 1—table 5 and Appendix 1—table 6). Over half of the children enrolled after baseline were born into study sites (336/622 [54%], Figure 1).

Our main analyses included observations from all eligible children enrolled at baseline (mean sampling age 664 days, SD = 393) and the 12-month (940 days, SD = 498) and 24-month (1137 days, SD = 603) follow-up visits (Table 2). We used a difference-in-difference (DID) analysis to estimate the intervention effect and adjust for baseline differences between intervention and control compounds. We present effect estimates from the DID analyses as prevalence ratios (ratio of ratios). To assess the validity of the parallel trend assumption, a key assumption of DID analyses, we ran ‘placebo tests’ by replacing outcomes with variables unrelated to the intervention, such as child age, respondent role, and presence of animals. Placebo tests showed no effect of the intervention on these variables, suggesting the parallel trend assumption was valid. We found no evidence that the intervention had an effect on the prevalence of any bacterial or protozoan infection (adjusted PR 1.04, 95% CI [0.94–1.15]), or any STH re-infection (1.11 [0.89–1.38]) 12 months after implementation (Table 2) despite household respondents reporting almost exclusive use of the intervention latrine (97%, 404/417). The prevalence of diarrhea remained fairly constant in both arms in all three phases with the exception of the 12-month measure in the control arm which was lower, resulting in a larger effect estimate with low precision (1.69 [0.89–3.21]).

The intervention had no meaningful effect at 12 months on the prevalence of infection with any of the three pathogen types measured by the GPP (bacterial, protozoan, viral), pathogen coinfection, or on any individual pathogen (Table 2). There was poor precision in the effect estimates for infrequently detected pathogens, evident from their wide confidence intervals. Therefore, some estimates suggestive of a large protective or detrimental effect (Campylobacter, C. difficile, E. coli O157, STEC, Norovirus GI/GII, Adenovirus 40/41) may have arisen by chance. While the National Deworming Campaign (NDC) provided albendazole to all compound members following baseline, during 12-month visitation only 58% of caregivers (56% control, 60% intervention) confirmed that their child was dewormed during these visits. A sensitivity analysis restricted to children confirmed to have been dewormed produced similar results to the main analysis (Appendix 1—table 7). By the 12-month visit, 19 control compounds (19/240 [8.0%]) had independently upgraded their facilities to pour-flush toilets. Results from sensitivity analyses excluding children living in control compounds with independently upgraded facilities were consistent with the main results (Appendix 1—table 8).

There was no evidence that the intervention had an effect on the prevalence of any bacterial or protozoan infection, any STH re-infection, or diarrhea after 24 months among all enrolled children (Table 2). We also found limited evidence of effect on the prevalence of any pathogen type or coinfection with ≥2 GPP pathogens 24 months after intervention. Results for several individual outcomes were suggestive of a protective (STEC, E. coli O157, Cryptosporidium, STH coinfection) or adverse (Campylobacter, C. difficile) effect, but evidence was weak as estimates were accompanied by wide confidence intervals and chance discoveries were possible given multiple comparisons. At the 24-month visits, caregivers confirmed baseline and/or 12-month deworming more frequently for intervention children (339/502 [68%]) than for control children (286/499 [57%]). Adjustment for deworming status or time since deworming had no impact on effect estimates (Appendix 1—table 7). Excluding children from control compounds which independently upgraded their facilities by the 24-month visit (35/211 compounds, [17%]) did not impact the results (Appendix 1—table 8).

Point estimates of effect and associated confidence intervals were largely similar in unadjusted and adjusted models with few exceptions (e.g. ETEC at 24 month) (Table 2). Multivariable models for GPP outcomes and STH outcomes were adjusted for covariates selected a priori (child age, sex, caregiver education, and household wealth index). No other variables met our inclusion criteria for multivariable models, which included being imbalanced between intervention and control at baseline and meaningfully changing 12-month effect estimates (>10% change in prevalence ratios) (Appendix 1—table 9). While the relationship between age and pathogen prevalence appeared to be non-linear for many pathogens (Appendix 1—figure 4), the inclusion of a higher order age term (age squared) did not meaningfully change effect estimates in the main or sub-group analyses (Appendix 1—table 10). Three measures of seasonality were considered for inclusion in multivariable models to adjust for any difference in seasonal distributions of data collection: (1) a binary variable defining the ‘rainy’ (November – April) and ‘dry’ seasons (May – October) in Maputo, (2) a measure of cumulative rainfall (mm) in the 30 days prior to data collection, and (3) sine and cosine terms representing dates of sample collection. While there was some imbalance between arms in data collected during the wet and dry seasons at baseline (Appendix 1—table 9), no measure of seasonality meaningfully changed effect estimates in the 12- and 24-month analyses and seasonality was excluded from final multivariable models (Appendix 1—table 9 and Appendix 1—table 11). For diarrhea, two variables in addition to variables selected a priori met our inclusion criteria and were included in adjusted models: presence of a latrine drop-hole cover at baseline and reported use of a water tap located within the compound grounds at baseline (Appendix 1—table 9). The magnitude of effect estimates were larger and confidence intervals wider for diarrhea in adjusted versus unadjusted models in the 12-month and 24-month analyses (Table 2).

In addition to the main analyses which included all enrolled children, we also performed two sub-group analyses. The first included children who were born after the intervention was implemented (or after baseline in control compounds) and present at the 12- and/or 24-month follow-up visit. This analysis allowed us to evaluate the impact of the intervention on young children who were never exposed to poor sanitation at baseline. The second sub-group analysis included only children with repeated measures at baseline and 12- and/or 24-month follow-up.

In sub-group analyses comparing children born into study compounds before the 24-month visit with children of similar ages at baseline (<2 years old), there was suggestive evidence that the intervention reduced the prevalence of infection with any STH by 49% (n = 522; adjusted prevalence ratio 0.51, [95% CI 0.27–0.95]), Trichuris by 76% (n = 522; 0.24, [0.10–0.60]), and Shigella by 51% (n = 630; 0.49, [0.28–0.85]) (Table 3). These effects were attenuated in sub-group analyses restricted to older children (>24 months) who were born before the intervention was implemented and present at the 24-month phase (Appendix 1—table 12). We did not observe intervention effects among children born into the study by the 12-month visit, but the sample size was small, resulting in high uncertainty in effect estimates (Appendix 1—table 13).

Table 3
Effect of intervention on bacterial, protozoan, viral, and STH infection and reported diarrhea in children born into study sites post-intervention (post-baseline) but by 24-month visit compared with children of a similar age at baseline (<2 years old).
Prevalence (<2 years old)Prevalence ratio (95% CI), p-value
Baseline24 month, Born-inUnadjustedAdjusted
Any bacterial or protozoan infection*
Control158/228 (69%)79/106 (75%)....
Intervention129/201 (64%)71/107 (66%)0.96 (0.77–1.21), p=0.740.99 (0.80–1.22), p=0.92
Any STH infection*
Control67/205 (33%)25/68 (37%)....
Intervention52/183 (28%)13/75 (17%)0.52 (0.26–1.05), p=0.0690.51 (0.27–0.95), p=0.035
Diarrhea*
Control46/283 (16%)18/105 (17%)....
Intervention43/238 (18%)22/100 (22%)1.20 (0.57–2.5), p=0.641.37 (0.47–4.03), p=0.57
Any bacteria
Control142/228 (62%)70/106 (66%)....
Intervention102/201 (51%)51/107 (48%)0.89 (0.66–1.20), p=0.440.90 (0.67–1.19), p=0.45
Shigella
Control67/228 (29%)36/106 (34%)....
Intervention49/201 (24%)15/107 (14%)0.48 (0.28–0.83), p=0.0090.49 (0.28–0.85), p=0.011
ETEC
Control70/228 (31%)30/106 (28%)....
Intervention58/201 (29%)24/107 (22%)0.84 (0.46–1.52), p=0.560.85 (0.48–1.51), p=0.58
Campylobacter
Control27/228 (12%)14/106 (13%)....
Intervention14/201 (7%)13/107 (12%)1.75 (0.63–4.87), p=0.291.75 (0.61–4.98), p=0.30
C. difficile
Control20/228 (8.8%)7/106 (6.6%)....
Intervention13/201 (6.5%)7/107 (6.5%)1.33 (0.36–4.86), p=0.671.49 (0.41–5.44), p=0.55
E. coli O157
Control7/228 (3.1%)3/106 (2.8%)....
Intervention9/201 (4.5%)2/107 (1.9%)0.45 (0.06–3.66), p=0.460.53 (0.07–4.24), p=0.55
STEC
Control1/228 (0.44%)2/106 (1.9%)....
Intervention9/201 (4.5%)1/107 (0.93%)0.05 (0.00–1.13), p=0.0590.05 (0.00–1.26), p=0.070
Any protozoa
Control82/228 (36%)47/106 (44%)....
Intervention74/201 (37%)43/107 (40%)0.84 (0.55–1.28), p=0.420.90 (0.62–1.30), p=0.58
Giardia
Control79/228 (35%)44/106 (42%)....
Intervention68/201 (34%)41/107 (38%)0.90 (0.58–1.39), p=0.630.93 (0.64–1.36), p=0.70
Cryptosporidium
Control7/228 (3.1%)5/106 (4.7%)....
Intervention12/201 (6%)5/107 (4.7%)0.45 (0.08–2.57), p=0.370.64 (0.12–3.51), p=0.61
Any virus
Control34/228 (15%)18/106 (17%)....
Intervention36/201 (18%)18/107 (17%)0.83 (0.37–1.83), p=0.640.83 (0.37–1.87), p=0.66
Norovirus GI/GII
Control26/228 (11%)12/106 (11%)....
Intervention26/201 (13%)17/107 (16%)1.24 (0.48–3.17), p=0.661.29 (0.49–3.41), p=0.61
Adenovirus 40/41
Control7/228 (3.1%)4/106 (3.8%)....
Intervention7/201 (3.5%)0/107 (0.0%)..§..§
Coinfection, ≥2 GPP pathogens
Control92/228 (40%)52/106 (49%)....
Intervention74/201 (37%)39/107 (36%)0.82 (0.56–1.21), p=0.330.86 (0.59–1.24), p=0.41
Trichuris
Control48/205 (23%)18/68 (26%)....
Intervention41/183 (22%)5/75 (6.7%)0.25 (0.09–0.68), p=0.0060.24 (0.10–0.60), p=0.002
Ascaris
Control45/205 (22%)16/68 (24%)....
Intervention29/183 (16%)9/75 (12%)0.70 (0.30–1.64), p=0.420.68 (0.30–1.54), p=0.36
Coinfection, ≥2 STH
Control26/205 (13%)9/68 (13%)....
Intervention18/183 (9.8%)1/75 (1.3%)0.13 (0.02–1.08), p=0.0590.12 (0.01–1.02), p=0.052
  1. Analysis includes children < 2 years old at baseline and children born into the study after baseline and <2 years old at the time of the 24-month visit. Prevalence results are presented as (n/N (%)). All effect estimates are presented as prevalence ratios (ratio of ratios) and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors.

    *Outcome was pre-specified in trial registration. All other outcomes are exploratory.

  2. Pathogen outcomes adjusted for child age and sex, caregiver’s education, and household wealth index. Reported diarrhea was also adjusted for baseline presence of a drop-hole cover and reported use of a tap on compound grounds as primary drinking water source. Sample sizes for adjusted analyses are slightly smaller than numbers presented in prevalence estimates due to missing covariate data.

    §Models would not converge due to sparse data. Y. enterocolitica, V. cholerae, E. histolytica, and rotavirus were detected in <2% of samples in each arm at each phase and excluded. Descriptive data for these pathogens are available in the Appendix 1—table 2. Source files available in Table 3—source data 1 and Table 3—source code 1.

Table 3—source code 1

Intervention effect on children born after implementation.

https://cdn.elifesciences.org/articles/62278/elife-62278-table3-code1-v3.zip
Table 3—source data 1

Intervention effect on children born after implementation.

https://cdn.elifesciences.org/articles/62278/elife-62278-table3-data1-v3.xlsx

Longitudinal sub-group analyses explored the effect of the intervention on children with repeated measures at baseline and 12 month (for unadjusted analyses: n = 870 data points [435 children with repeat measures] for GPP outcomes, n = 572 [286] for Kato-Katz outcomes, and n = 1112 [556] for diarrhea) and at baseline and 24 month (n = 716 (358), n = 402 (201), n = 834 (417)). Effect estimates were consistent with results from the main analyses (Appendix 1—table 14 and Appendix 1—table 15) but less precise due to the reduced sample numbers.

Discussion

We found no evidence that this urban, onsite shared sanitation intervention was protective against our pre-specified child health outcomes of enteric infection, STH re-infection, or diarrhea. We also found no strong evidence that the intervention affected prevalence of any individual pathogen, pathogen type, or coinfection with ≥2 enteric pathogens or STH. In exploratory sub-group analyses, we found suggestive evidence that the intervention reduced the prevalence of any STH, Trichuris, and Shigella infections among children born into the study by the 24-month follow-up visit. Studying children born into intervention sites after implementation allowed us to examine the effect of the intervention from birth through the first 2 years of life. These results suggest that the intervention delayed pathogen exposure and the accumulation of enteric infections during early childhood, but need to be treated with caution as this was an exploratory subgroup analysis.

The trial was neither designed nor powered to detect differences in sub-groups of children such as those born after the intervention was implemented, potentially limiting our ability to detect small effects in such analyses. Further, all exploratory sub-group analyses included multiple comparisons, increasing the likelihood of chance discoveries. However, the magnitude of the effect estimates for the outcomes of any STH, Trichuris, and Shigella observed among children born into the study by the 24-month visit, and the directional consistency of effect estimates among most other outcomes in this sub-group analysis, strengthens the plausibility of these findings.

There are several reasons we observed suggestive evidence of an effect for some outcomes among this sub-group of young children but not among older children or in the main analyses. Children’s exposures vary by age, particularly as they become mobile and begin independent exploration of their environment. It is possible that the intervention reduced exposure via pathways that are important for very young children but may represent just minor pathways of exposure among older children (Kwong et al., 2020). Additionally, young children may experience fewer exposures outside of the compound. Reductions in exposure and subsequent infection early in life may delay or prevent the development of environmental enteric dysfunction (EED), a subclinical condition that affects the structure and function of the gut and may increase susceptibility to future infection (Keusch et al., 2014; Prendergast and Kelly, 2016). Results from the EED sub-study of the WASH Benefits cluster randomized controlled trial (cRCT) in Bangladesh suggest that the intervention delayed but did not prevent the onset of EED (Lin et al., 2019). If this intervention similarly delayed the development of EED among children born into intervention sites, they may have been less susceptible to infection than children of a similar age at baseline. Finally, some pathogens, like Giardia and certain STH, can cause persistent infections that can remain active for months or years if not treated (Else et al., 2020; Rogawski et al., 2017). The intervention would have no effect on such infections, highlighting the potentially important role of protection from birth.

Notably, both Shigella and Trichuris are primarily anthroponotic, and infection was strongly age-dependent in this study population (Knee et al., 2018). These factors may help explain the differing intervention effects observed both among pathogens and age groups. The intervention was unlikely to limit exposure to animal feces, reducing the likelihood that it would impact the infection prevalence of zoonotic pathogens like Campylobacter or Giardia. The strong positive associations between age and prevalence for Shigella and Trichuris suggest that exposure increases with age. This supports the hypothesis that the intervention may have reduced the overall frequency or intensity of exposure enough to impact Shigella and Trichuris infection among young children but not older children.

Rapid urbanization is expanding informal settlements and out-pacing the expansion of sanitation services in many cities, widening the gap in sanitation access between the urban rich and poor (UNICEF/WHO, 2019). To our knowledge, MapSan was the first trial to estimate the health impact of an urban, onsite shared sanitation intervention and the first to use enteric infection as the primary trial outcome. Most of the urban sanitation literature published to date has evaluated the expansion of sewerage, an important and ambitious goal that is out of reach for many cities in the near-term (Norman et al., 2010). Access to sewerage is associated with a 30–60% reduction of diarrheal disease depending on starting conditions, and an approximately 30% reduction in enteric parasite detection, though most studies are observational and few controlled trials exist (Barreto et al., 2010; Norman et al., 2010; Wolf et al., 2018).

Most studies of onsite sanitation interventions have occurred in rural areas. Despite good evidence that onsite sanitation is associated with reductions in diarrheal disease (Freeman et al., 2017a; Wolf et al., 2018), several recent rural trials of basic sanitation and combined WASH interventions with good uptake and use reported mixed effects on child health outcomes including diarrhea, linear growth, and more recently, enteric infection (Ercumen et al., 2019; Grembi et al., 2020; Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial Team et al., 2019; Lin et al., 2018; Luby et al., 2018; Null et al., 2018; Pickering et al., 2019; Rogawski McQuade et al., 2020a).

The Sanitation, Hygiene, Infant Nutrition Efficacy (SHINE) trial in rural Zimbabwe found no impact of a combined WASH intervention on diarrhea, growth, or the prevalence of a suite of enteric pathogens among children aged <12 months old but did report a small reduction in the number of parasitic pathogens detected (Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial Team et al., 2019; Rogawski McQuade et al., 2020a).

While the WASH Benefits Bangladesh cRCT reported no effect of any WASH intervention on child growth, the sanitation, hygiene, and combined WASH study arms reduced the prevalence of diarrheal disease from 5.7% to 3.5% (Luby et al., 2018), accompanied by absolute reductions in Giardia prevalence of 6–9% among children aged 2–3 years in the same arms (Lin et al., 2018). The sanitation arm also reduced the prevalence of T. trichiura among children 2–3 years old (from 5.2% to 3.2%) but had no impact on A. lumbricoides or hookworm, the only other parasites detected frequently enough to estimate effects in that study (Ercumen et al., 2019). In a parallel analysis, only the water treatment and combined WASH interventions of the WASH Benefits Kenya cRCT reduced the prevalence of A. lumbricoides, suggesting that the reduction in the combined WASH arm may be attributable to the water treatment intervention (Pickering et al., 2019). The sanitation-only arm had no impact on any parasite measured, although T. trichiura was too infrequently detected to estimate effects (Pickering et al., 2019). An evaluation of a comprehensive suite of 34 enteric pathogens reported reduced prevalence and quantity of enteric viruses, but not bacteria or parasites, among children aged 14 months old in the combined WASH arms in the Bangladesh trial (Grembi et al., 2020). Together with our findings, these results suggest that sanitation and combined WASH interventions can reduce the prevalence of enteric infection in some settings but that effects may vary by pathogen, child age, intervention, and setting.

We previously published two baseline risk factor analyses to identify demographic, environmental, and WASH-related predictors of infection and environmental fecal contamination in our study setting prior to the intervention implementation (Holcomb et al., 2020; Knee et al., 2018). Age was an important predictor of infection, although the direction of its effect varied by pathogen type. Increasing age was associated with increased risk of bacterial and protozoan infections and decreased risk of viral infections (Knee et al., 2018). Other socio-demographic predictors of infection included breastfeeding, which was associated with a decreased risk of any infection (driven by its strong association with protozoan infection), and female sex which was associated with an increased risk of viral infection. Few sanitation-related or environmental variables were associated with infection at baseline and the magnitude of associations were often small. The presence of a latrine superstructure and drop-hole cover were associated with small reductions in risk of bacterial or protozoan infection, often only in unadjusted analyses, but other latrine features (e.g. presence of a cleanable slab) were not. The observation of feces or used diapers around the compound grounds was associated with increased risk of bacterial and protozoan infection but most other environmental and sanitary hazards were not (Knee et al., 2018).

Fecal contamination was common among all environmental reservoirs tested (water, soil, food preparation surfaces) at baseline. We detected one or more microbial markers of contamination in over 95% of environmental samples (Holcomb et al., 2020). E. coli was the most frequently detected and abundant marker of contamination among all sample types, and human-associated markers were most frequently detected in soil (59%) and stored drinking water (17%) samples. Measures of latrine quality that were associated with small reductions in infection risk (e.g. drop-hole covers, latrine superstructures) were not associated with decreased odds of fecal contamination in this setting. Overall, we found few consistent relationships between markers of fecal contamination and environmental, WASH-related, and demographic characteristics at baseline (Holcomb et al., 2020).

While these results suggest WASH-related and environmental risk factors may be poor determinants of child health in this setting, the lack of heterogeneity in WASH conditions at baseline, given the selection criterion that compounds must share sanitation in ‘poor condition,’ may have limited our ability to identify strong WASH-related predictors of infection or environmental fecal contamination. Results from a forthcoming companion study suggests the intervention had mixed effects on environmental fecal contamination. The intervention may have reduced the concentration of E. coli by an order of magnitude in soil collected from latrine entrances after 12 months; however, there was no effect on the prevalence or concentration of indicators of fecal contamination in any other environmental compartment sampled at that time (Holcomb et al., 2021). It is unlikely that the observed reductions in fecal contamination in soils alone would be sufficient to impact health outcomes in this setting. Other studies that have evaluated the impact of sanitation interventions on fecal contamination of the surrounding environment have found limited evidence of effect (Clasen et al., 2014; Ercumen et al., 2018a; Ercumen et al., 2018b; Fuhrmeister et al., 2020; Patil et al., 2014; Pickering et al., 2015; Sclar et al., 2016; Steinbaum et al., 2019).

In this setting, where fecal contamination was pervasive and burden of infection high, even considerable reductions in contamination and exposure may have been insufficient to realize measurable health gains as the intervention did not address all potential transmission pathways (Briscoe, 1984; Julian, 2016; Robb et al., 2017). For example, the intervention did not address child feces disposal practices or handwashing behaviors and it is unlikely that the intervention infrastructure would have changed these (Cochrane Infectious Diseases Group et al., 2019). Previous studies of sanitation interventions have found no reduction in hand contamination (Ercumen et al., 2018b), which has been associated with increased incident diarrheal disease in young children (Pickering et al., 2018). The intervention may not have reduced exposure via consumption of contaminated food – particularly foods contaminated prior to arrival in the compound – likely an important source of enteric pathogen transmission in some settings (Julian, 2016; Kwong et al., 2020). Children’s exposure to animal feces has been documented in rural, peri-urban, and urban settings and could be an important, unmitigated source of exposure to enteric pathogens in both intervention and control arms where animals were frequently observed (Delahoy et al., 2018; Kwong et al., 2020; Penakalapati et al., 2017). Observation of animals in compounds was examined as a potential confounder but did not change effect estimates.

The intervention was delivered at the compound level, not the community level, and was not designed to achieve any specified threshold of sanitation coverage in the study neighborhoods. Previous studies have suggested that achieving a certain level of community sanitation coverage may be necessary to reduce disease burdens (Barreto et al., 2007; Fuller and Eisenberg, 2016; Fuller et al., 2016; Harris et al., 2017; Jung et al., 2017; Spears et al., 2013; Wolf et al., 2018). For example, a study of a large-scale sewerage expansion in urban Brazil found that the intervention reduced diarrheal disease by 22%, with neighborhood coverage level being the single most important explanatory variable (Barreto et al., 2007). We did not measure neighborhood-level sanitation coverage, but previous estimates show that while coverage is high and open defecation is limited (1%), only 9% of sanitation systems are safely managed (Satterthwaite et al., 2019). Further, in the Nhlamankulu district where many of our study sites are located, the majority of households (56%) rely on private pit latrines, most of which are in poor condition (Devamani et al., 2014; Satterthwaite et al., 2019). Together with our results, this suggests that both the extent and quality of community coverage are likely important to reducing overall transmission. Sanitation coverage and quality may be especially important in urban areas given the proximity of compounds and the opportunity for person-to-person contact, neighborhood-level exposure, and for external sources of contamination (e.g. a neighbor’s flooded pit latrine) to influence compound-level exposures (Barreto et al., 2007). We did not measure neighborhood-level exposures, which may be important for young children in slum settings (Ezeh et al., 2017; Medgyesi et al., 2019), and their impact on our health outcomes is unclear. In addition to neighborhood-level exposures, the transience of the study population meant that trips to and from provinces outside of Maputo, where exposures were varied and unmeasured, were common.

It is unlikely that our findings are due to poor intervention fidelity or use, a challenge encountered in some trials of rural sanitation interventions (Clasen et al., 2014; Patil et al., 2014). The use of the intervention required minimal behavior change as compound members switched from using their existing latrine in poor condition, which was removed following construction of the intervention latrine, to using the new hygienic latrine. The results of a forthcoming process evaluation demonstrate that 96% of intervention latrines were well-maintained 2 or more years after construction, suggesting continued use by compound members (Bick, 2021). Further, only 3% of intervention compounds (8/270) had a secondary, non-intervention latrine in use after two or more years, indicating that members of most intervention compounds exclusively used the intervention latrines (Bick, 2021). It is possible that development in the study neighborhoods, including changes to sanitation facilities in control compounds, contributed to the limited effect of the intervention. However, results from sensitivity analyses that excluded control compounds with upgraded sanitation were consistent with results from the main analyses.

The two intervention designs we evaluated in this study – communal sanitation blocks and shared latrines – utilized the same basic sanitation technology but differed in the number of cabins and amenities available. While it is possible that this heterogeneity in design may have modified the effect of the intervention, this study was not powered to test this. Moreover, all intervention compounds were encouraged to independently upgrade their facilities by adding features like electricity and handwashing stations, or by connecting existing handwashing stations to the water supply, resulting in heterogeneity even within the two broad categories of intervention type.

While the NDC dewormed every study compound annually during the study period, it is possible that not all study participants received, or took, the medication and that the time between deworming and subsequent measurement of STH re-infection varied among children. Additionally, single-dose albendazole can have limited effectiveness against certain STH, notably Trichuris (Moser et al., 2017). Inadequate or ineffective deworming could have limited our ability to detect an effect on STH outcomes. Sensitivity analyses adjusting for caregiver-confirmed deworming and for estimated time between deworming and re-infection measurement produced similar results to the main analysis.

There are several important limitations of this study. As the intervention was pre-planned and not implemented by the study team, we could not randomize its allocation, increasing the risk of confounding. We assessed potential confounding variables at baseline and used a DID analysis, which accounts for baseline outcome measures, to limit the effect of unmeasured, residual confounding. While we attempted to enroll intervention and control compounds with comparable numbers of residents, the NGO which identified and implemented the intervention selected most of the largest eligible compounds for intervention. This resulted in intervention compounds having a slightly higher mean number of residents than control compounds (Table 1). Crowding has been identified as a risk factor for pathogen transmission and poor health outcomes in other studies (Halpenny et al., 2012; Rahman et al., 1985; Rogawski McQuade et al., 2020b), although we found limited evidence of this in our study population at baseline (Knee et al., 2018). Further, we assessed the number of compound residents as a potential confounder but found that it did not meaningfully change the DID estimates for our pre-defined outcomes (Appendix 1—table 9). We consider our analysis to be robust to small differences in study arms at baseline; however, we cannot exclude the possibility of residual confounding due to such differences, a limitation of non-randomized designs.

It was not possible to mask participants to their intervention status, and our measure of caregiver-reported diarrhea could be subject to respondent and recall biases. To reduce the risk of respondent bias, the MapSan field enumerator team and implementation team were different, and respondents were not informed explicitly that the MapSan team was evaluating the health effect of the intervention. To limit recall bias, we used a 7-day recall period (Arnold et al., 2013). Our other pre-specified outcomes were objective measures of pathogen infection and not subject to the same biases (Brown and Cumming, 2020).

Due to the greater than expected losses to follow-up in both study arms, we were not able to follow all children enrolled at baseline through time as expected, but we still achieved our target enrollment numbers due to migration and births into study compounds. We conducted the originally planned longitudinal analysis as a sub-group analysis. It also served as a sensitivity analysis to estimate the impact of migration on our effect estimates. Results from this sub-group analysis were largely similar to results of the main analysis which treated measures as repeated cross-sections, although the reduction in sample size led to wider confidence intervals (Appendix 1—table 14 and Appendix 1—table 15). Measures of outcomes and covariates in children with and without repeated measures were mostly similar, further limiting the likelihood that changes in the study population biased our results.

While molecular detection of enteric pathogens in stool is evidence of pathogen exposure, it is not necessarily evidence of active infection, making its clinical significance less clear (Brown and Cumming, 2020). We assumed pathogen detection by the GPP indicated infection because the assay’s limits of detection exceeded the median infectious dose of most pathogens. While the GPP detects many enteric pathogens recognized as important causes of childhood diarrhea in LMICs, (Liu et al., 2016) it does not detect all enteric pathogens of importance. Further, qualitative, cross-sectional analysis of stools does not provide information on the duration or intensity of infection or pathogen carriage. Quantitative results like those produced by multiplex quantitative PCR panels can be used to aid identification of etiologic agents of diarrhea, especially in cases of coinfection, and to differentiate between low-level enteric pathogen detection of unknown clinical relevance and higher concentration shedding which is more clearly associated with disease (Liu et al., 2014; Liu et al., 2016; Platts-Mills et al., 2013). Some studies have demonstrated overall good performance of the GPP but observed elevated false positive detection rates for the Salmonella targets (Duong et al., 2016; Kellner et al., 2019). For this reason we removed Salmonella results from our pre-specified outcome definition. Results from analyses including and excluding Salmonella were similar. In addition, some studies have observed reduced sensitivity or specificity for some GPP targets compared with qPCR-based methods, including norovirus, adenovirus, Campylobacter, Yersinia enterocolitica, ETEC, and Salmonella, although inconsistencies between studies exist and are likely due to differences in comparator assays or sample storage and processing (Chhabra et al., 2017; Deng et al., 2015; Duong et al., 2016; Huang et al., 2016; Zhan et al., 2020; Zhuo et al., 2017). Further, the lack of an adequate reference standard in most comparative studies complicates interpretation (Freeman et al., 2017b).

Our ability to detect an effect on our primary outcome, the prevalence of ≥1 bacterial or protozoan infection, may have been limited by (1) the extended duration of shedding of some pathogens following active infection; (2) the overall high burden of disease in our study population, particularly among older children; and (3) residual confounding by age given the strong observed relationship between age and infection status (particularly for protozoan pathogens), all of which may have biased our results toward the null. Further, the intervention may have impacted the concentration of pathogens shed (Grembi et al., 2020; Lin et al., 2019), but our binary outcome was not sensitive to such differences The qualitative nature of the GPP did not allow us to interrogate this question.

We analyzed a smaller number of stool samples for STH than for other enteric pathogens due to requirements of the Kato-Katz method used for STH detection. The Kato-Katz method can only be performed on whole, solid stool. Diarrheal samples and rectal swabs, the latter of which were introduced during the 12-month follow-up phase, were not eligible for STH analysis by Kato-Katz. Further, when limited stool material was collected, we prioritized the molecular analysis used for the primary outcome. While the smaller sample size available for the STH analyses may have reduced our ability to detect small effects, the proportions of whole stool, diarrheal diaper samples, and rectal swabs were similar between arms at each phase (Appendix 1—table 1). This limited the potential impact that sample type could have on our results.

While the Kato-Katz method performs similarly to other microscope-based and molecular methods for detection of moderate- to high-intensity infections, it may be less sensitive than molecular methods in detecting low-intensity infections (Benjamin-Chung et al., 2020; Cools et al., 2019). A recent study has also suggested reduced specificity of the Kato-Katz method for detection of low-intensity A. lumbricoides infections (Benjamin-Chung et al., 2020). In settings where low-intensity infections are common, or where STH may be targeted for elimination, methods with better diagnostic accuracy, like qPCR, may be considered.

We had limited ability to evaluate the impact of seasonality or weather-related trends on our effect estimates due to drought conditions during the 2015/2016 rainy season. We adjusted models for cumulative 30-day rainfall, a binary indicator of wet/dry season, and sine/cosine terms of sample collection date (Stolwijk et al., 1999) but excluded all seasonality terms from final multivariable models because they did not meaningfully change effect estimates.

Our results demonstrate that access to hygienic, shared onsite sanitation systems was not sufficient to reduce enteric infection or diarrhea in children aged 6 years or younger (≤4 at baseline) 12–24 months after implementation. Results from our sub-group analysis of children born into intervention sites showed a substantial reduction in the prevalence of any STH, Trichuris, and Shigella infection, suggesting that children may require protection from birth to reduce or delay infection burdens. Our results do not suggest that shared sanitation is inadvisable in this setting, as we did not compare against household-level sanitation improvements, nor do they account for the many non-health-related benefits associated with this intervention or upgraded sanitation generally (Caruso et al., 2018; Sclar et al., 2018; Shiras et al., 2018).

The need for effective sanitation solutions may be most urgent in densely populated, low-income, informal communities like our study setting where ubiquitous fecal contamination drives high infection burdens. Disease transmission in these settings may be driven by multiple interrelated pathways, complicated by frequent migration and the diversity of circulating pathogens, and therefore difficult to interrupt. While decades of research have demonstrated meaningful health gains following sanitation improvements, the results of this study and other rigorous trials of sanitation interventions suggest that the relationship between sanitation and health is complex, difficult to measure, and may not be generalizable across diverse settings and populations.

Materials and methods

Study design and intervention

Request a detailed protocol

MapSan was a controlled before-and-after trial, and details of the study design and analysis plan have been published previously (Brown et al., 2015). We conducted the study in 16 densely populated, low-income, informal neighborhoods in Maputo, Mozambique. The intervention was delivered to compounds, typically groups of three to five households (although larger and smaller compounds exist) often delineated by a wall or barrier, that shared sanitation and outdoor living space. Shared compound sanitation facilities are not considered public facilities. We collected data in an open cohort of children in intervention and control compounds at three time-points: baseline (pre-intervention), 12 months post-intervention, and 24 months post-intervention.

The NGO Water and Sanitation for the Urban Poor selected intervention compounds and designed and built 300 intervention facilities – pour-flush toilets discharging to septic tanks, the liquid effluent of which flows to the soil through soakaway pits (Appendix 1—figure 5 and Appendix 1—figure 6). There were two intervention designs with the same basic sanitation technology: communal sanitation blocks (CSBs) and shared latrines (SLs) (Appendix 1—figure 7 and Appendix 1—figure 8). The primary difference between CSBs and SLs was size. CSBs (n = 50) included multiple stalls with toilets and served compounds of 21 or more people with one stall allocated per 20 residents. CSBs also included rainwater harvesting systems, a municipal shared water connection, elevated water tanks for storage of municipal water, a handwashing basin, a laundry facility, and a well-drained area for bathing. Shared piped water connections were part of the municipal water system and could be used for drinking in addition to other domestic purposes. Rainwater was intended for cleaning and flushing but not drinking. Shared latrines (n = 250) were single-stall facilities serving fewer than 21 people. All septic tanks were sized to require emptying after approximately two years.

Intervention compounds were located in 11 neighborhoods of the Nhlamankulu and KaMaxakeni districts of Maputo (Appendix 1—figure 9). The NGO selected intervention compounds using the following criteria: (1) residents shared sanitation in poor condition as determined by an engineer; (2) the compound was located in the pre-defined implementation neighborhoods; (3) there were no fewer than 12 residents; (4) residents were willing to contribute financially to construction costs; (5) sufficient space was available for construction of the new facility; (6) the compound was accessible for transportation of construction materials and tank-emptying activities; (7) the compound had access to a legal piped water supply; and (8) the groundwater level was deep enough for construction of a septic tank. Intervention compounds were expected to pay approximately 10–15% of the construction costs (~$64 for shared latrines and ~$97 for CSBs) within one year of construction, with 25% of the total due upfront. Presence of a child was not a selection criterion and therefore not all intervention sites were included in the study. Opening of newly constructed intervention latrines occurred between February 2015 and February 2016. The study team used criteria 1, 3, 4, and 7 to select control sites that had at least one child younger than 48 months old in residence. We enrolled intervention and control compounds concurrently to limit any differential effects of seasonality or other secular trends on the outcomes (Appendix 1—figure 2). Additionally, we attempted to enroll control compounds with similar numbers of residents as intervention compounds. Willingness to pay for facilities among controls was assessed using hypothetical versions of questions posed to interventions. Control compounds were located within the 11 intervention neighborhoods and 5 adjacent but similar neighborhoods due to the limited availability of eligible compounds remaining within intervention neighborhoods (Appendix 1—figure 9). Intervention selection criteria (5, 6) and (8) were not used to select control sites as they were deemed to be related to intervention construction and maintenance and unlikely to influence our outcomes. It was not possible to blind participants or enumerators to intervention status.

Participants

We enrolled eligible children at three time points: baseline (0 months), 12 months post-intervention, and 24 months post-intervention. Children aged 1–48 months old were eligible for baseline enrollment if we received written informed consent from a parent or guardian and if the head of the compound provided verbal assent for the compound to be included in the study. Children were eligible for enrollment at 12- and 24-month visits if they were aged 1–48 months or if they were eligible for enrollment at baseline but absent during that study visit. Children who moved into the compound fewer than 6 months before the 12-month or 24-month visit were not eligible for enrollment during that phase given their limited exposure to their new compound.

Procedures

Request a detailed protocol

Trained field enumerators completed consent procedures and surveys in the participant’s preferred language (Portuguese or Changana) and collected biological sampless from enrolled children (Appendix 1- Consent procedures, survey administration, and sample collection and analysis). At baseline we aimed to visit intervention compounds 2 weeks prior to the opening of the new latrines. We scheduled follow-up visits to be 12 months (±2 weeks) and 24 months (±2 weeks) from the date compound members began using their new latrines, with visits to control compounds made concurrently (±2 weeks).

We collected stool samples independently of reported symptomology. If we were unable to collect a stool sample after multiple attempts, a registered nurse collected a rectal swab after obtaining written consent for the procedure from a parent or guardian. Stool samples were kept cold and delivered to the Laboratory of Molecular Parasitology at the Instituto Nacional de Saúde (INS) within 6 hr of collection for analysis and storage at −80°C.

Samples were shipped frozen with temperatures monitors to the Georgia Institute of Technology (Atlanta, USA) where we used the xTAG GPP (Luminex Corp, Austin, USA), a qualitative multiplex molecular assay, to detect 15 enteric pathogens in stool samples: Campylobacter jejuni/coli/lari; Clostridium difficile, toxin A/B; enterotoxigenic Escherichia coli (ETEC) LT/ST; Shiga-like toxin producing E. coli (STEC) stx1/stx2; E. coli O157; Salmonella; Shigella boydii/sonnei/flexneri/dysenteriae; Vibrio cholerae; Yersinia enterocolitica; Giardia lamblia; Cryptosporidium parvum/hominis; Entamoeba histolytica; adenovirus 40/41; norovirus GI/GII; and rotavirus. The GPP has been rigorously tested and extensively used for stool-based enteric pathogen detection (Chisenga et al., 2018; Claas, 2013; Deng et al., 2015; Duong et al., 2016; Huang et al., 2016; Kellner et al., 2019; Khare et al., 2014; Navidad et al., 2013; Patel et al., 2014). We analyzed samples according to manufacturer instructions with the addition of elution steps for the pretreatment of rectal swabs and diaper material saturated with liquid stool (Appendix 1- Consent procedures, survey administration, and specimen collection and analysis). Technicians at INS assessed stool samples for the presence of soil-transmitted helminths (STH) using the single-slide Kato-Katz microscope method (Vestergaard Frandsen, Lausanne, Switzerland).

Representatives of the National Deworming Campaign (NDC) at the Mozambican Ministério da Saúde (MISAU) offered single-dose albendazole (400 mg, 200 mg for children aged 6–12 months) to all eligible members of intervention and control compounds following sample collection activities of each phase. Eligibility was defined by the NDC and included compound members older than 6 months who were not pregnant.

Outcomes

Request a detailed protocol

For the 12-month analysis, we pre-specified the primary outcome as infection with one or more of the 12 bacterial or protozoan enteric pathogens detected by the GPP and secondary outcomes as re-infection with one or more STH as detected by Kato-Katz (following albendazole treatment at baseline), and 7-day period prevalence of caregiver-reported diarrhea. All three outcomes were considered secondary outcomes in the 24-month analysis. We defined diarrhea as the passage of three or more loose or liquid stools in a 24 hr period or any stool with blood (Arnold et al., 2013; Baqui et al., 1991). We excluded viral enteric pathogens from the primary outcome definition. The intervention may not have interrupted virus transmission due to their low infectious doses, high concentration shed in feces and extended period of shedding, environmental persistence, and capability for direct person-to-person transmission (Julian, 2016). Following reported specificity issues with the Salmonella target of the GPP, we removed it from our GPP-based outcome definitions (Duong et al., 2016; Kellner et al., 2019). In addition to the pre-specified outcomes, we evaluated the effect of the intervention on specific pathogen types (bacterial, protozoan, viral) and on individual pathogens. The results for other secondary outcomes listed in the trial registration (growth and environmental enteric dysfunction) will be published separately.

Statistical analysis

Request a detailed protocol

Our sample size calculation has been described previously (Brown et al., 2015). We included all enrolled children at each visit and analysed data as repeated cross-sectional observations. We examined the effect of the intervention at the 12-month and 24-month phases separately. We conducted two sets of exploratory sub-group analyses. The first assessed the effect of the intervention on children with repeat observations at baseline and 12 months and at baseline and 24 months visits. These longitudinal analyses also served as sensitivity analyses of the impact of participant migration on effect estimates. The second sub-group analysis compared children who were born into study sites after the intervention (or after baseline in controls) but before the 12-month or 24-month visit with children of a similar age group at baseline. For example, children born after baseline but before the 24-month visit were compared with children aged 2 years old or younger at baseline. These analyses allowed us to explore whether exposure to the intervention from birth would reduce enteric pathogen infection during the first 1–2 years of life.

We used a DID approach to assess the impact of the intervention on all outcomes at the 12- and 24-month visits. We used generalized estimating equations (GEE) to fit Poisson regression models with robust standard errors. Our GEE models accounted for clustering at the compound level because it was the highest level of nested data and the level of the intervention allocation (Bottomley et al., 2016). We estimated the effect of the intervention as the interaction of variables representing treatment status (intervention versus control) and phase (pre- or post-intervention). Therefore, effect estimates from our DID analysis are presented as ratio measures (ratio of prevalence ratios) instead of absolute differences. Multivariable models were adjusted for covariates determined a priori as potentially predictive of our outcomes, including child age and sex, caregiver’s education, and household wealth. Given the important and potentially non-linear relationship between age and pathogen prevalence (Appendix 1—figure 4), we also considered inclusion of a higher order age term (age squared) in our models (Appendix 1—table 10). Additional covariates (Appendix 1—table 9) were considered for inclusion in multivariable models if they were imbalanced between arms at baseline (>0.1 standardized difference in prevalence or mean) and resulted in a meaningful change in the DID effect estimate (±10% change in 12-month DID prevalence ratio). We assessed the potential impact of seasonality on our results in three ways: (1) inclusion of binary indicator of wet (November – April) and dry (May – October) season in multivariable models, (2) inclusion of a variable representing cumulative rainfall (mm) 30 days prior to sample or survey collection in multivariable models, and (3) inclusion of sine and cosine functions of sample and survey dates in multivariable models (Appendix 1—table 9 and Appendix 1—table 11). We used the same statistical approach for sub-group analyses. All analyses were performed on complete case data, and a missing data table is presented in Appendix 1 (Appendix 1—table 16). We performed all statistical analyses with Stata version 16 (StataCorp, College Station, USA).

Registration

Request a detailed protocol

The trial was pre-registered at ClinicalTrials.gov (NCT02362932).

Appendix 1

Consent procedures, survey administration, and specimen collection and analysis

Enumerators visited households with enrolled children at least twice at each point of follow-up. On the first visit of each phase, enumerators completed consent procedures, administered child-, household-, and compound-level surveys, and delivered stool sample collection supplies. The child’s mother was the target respondent for child and household surveys, although the father or another guardian was also eligible. For compound-level surveys, the head of the compound or his or her spouse was the preferred respondent. We sought written, informed consent from the parent or guardian of each eligible child prior to initial enrollment. We sought verbal assent from parents or guardians at each follow-up visit. Consent procedures, surveys, and all study-related verbal communication was performed in Portuguese or Changana as requested by the participant. Written materials were provided in Portuguese.

Enumerators provided each caregiver with stool collection supplies, including disposable diapers, a plastic potty if the child was no longer wearing diapers, and a pre-labeled sterile sample bag. Enumerators returned the next day to collect the samples. If a sample was unavailable during the scheduled pickup, caregivers called the field team, using phone credit provided by the study, as soon as one was available or if fresh collection supplies were needed. If field enumerators were unable to collect a stool sample after multiple attempts, a registered nurse used an anatomically designed rectal swab (Copan Diagnostics Inc, Murrieta, CA, USA) to collect fecal material. Parents or guardians were required to complete a separate written consent procedure prior to collection of rectal swabs. Stool samples and rectal swabs were stored in coolers with cold packs and delivered to the Medical Parasitology Laboratory at the Mozambican Ministry of Health (MISAU/INS) within 6 hr of collection. Technicians at INS prepared Kato-Katz slides for soil-transmitted helminth (STH) detection the day of receipt and read results within 30 min of preparation for hookworm and within 24 hr for other STH. In addition to STH analysis, laboratory technicians at INS also aliquoted stools into several sterile tubes and stored them, and any rectal swabs, at −80°C. If a child produced a liquid stool, lab technicians stored a piece of the saturated diaper material (‘diaper samples’) at −80°C. Stool samples were shipped frozen on dry ice with temperature probes to the Georgia Institute of Technology in Atlanta, Georgia, USA where they were stored at −80°C until analysis.

We followed manufacturer instructions for the pretreatment, extraction, and analysis of stool samples by the Luminex Gastrointestinal Pathogen Panel (GPP), with additional elution steps added to the pretreatment protocol for rectal swabs and diaper samples. We eluted diaper samples in 2.5 mL of lysis buffer (ASL buffer, Qiagen, Hilden, Germany). We used a sterile 10 mL syringe to facilitate elution via agitation by taking in and expelling the buffer five times. We used 1 mL of the final eluate in the pretreatment. We agitated rectal swabs in 1 mL of lysis buffer for 1 min and used the eluate in the pretreatment. Following pretreatment, we extracted DNA and RNA using the QIAcube HT platform and the QIAamp 96 Virus QIAcube HT Kit (Qiagen, Hilden, Germany). We added MS2, a non-pathogenic RNA virus, to each sample prior to nucleic acid extraction as an extraction and RT-PCR inhibition control. We included at least one sample process control (containing only lysis buffer and MS2) and negative extraction control (containing only lysis buffer) with each set of extractions. During the PCR step we included at least one no-template control, containing molecular grade water and all PCR reagents with each run. To assess elution and extraction of nucleic acid from swab and diaper samples, we measured the concentration of double-stranded DNA (dsDNA) present in a subset of extracts using the Qubit High Sensitivity dsDNA kit (Invitrogen, Carlsbad, CA, USA) and Qubit 4 Fluorimeter (Invitrogen, Carlsbad, CA, USA). The mean concentration of dsDNA recovered from rectal swabs was 26.3 ng/μL (SD 15.5, n = 195, 25 swabs with measures above assay detection limit) and from diaper samples was 28.7 ng/μL (SD 16.9, n = 61, 16 diapers with measures above assay detection limit). The concentration of dsDNA recovered from whole stool exceeded the assay detection limits in most cases. The mean concentration of dsDNA in the subset of stools with measurable results was 40.8 ng/μL (SD = 16.5, n = 33, 57 samples had concentrations above the assay detection limit). Following extraction, we stored all extracts at 4°C and analyzed them by GPP within 24 hr. For long-term storage, we archived samples at −80°C. We extracted and analyzed approximately 10% of samples in duplicate (biological replicates). If duplicate analyses yielded different results, we combined the results from all analyses such that the final result captured all positive detections for a given sample. If we could not detect a MS2 signal in a given sample, we either re-extracted or diluted the extract 1:10 in molecular grade water and re-assayed by GPP.

Appendix 1—figure 1
Proportion of each type of sample collected during the baseline, 12-month, and 24-month phases.

Results stratified by study arm. Rectal swabs were not introduced until the 12-month phase of the study.

Appendix 1—table 1
Number and proportion of sample types collected in each arm at each phase.
Baseline12 month24 month
ControlInterventionControlInterventionControlIntervention
Whole stool377 (96%)351 (97%)361 (91%)380 (93%)307 (67%)333 (72%)
Diarrheal diaper15 (3.8%)10 (2.8%)4 (1.0%)4 (0.98%)32 (7.0%)20 (4.3%)
Rectal swab*0 (0%)0 (0%)30 (7.6%)24 (5.9%)120 (26%)109 (24%)
  1. *Mean concentration of double-stranded DNA recovered from whole stool was 40.8 ng/μL (SD = 16.5, n = 33 with 57 samples excluded as their concentrations exceeded the upper detection limit of the assay), diaper samples was 28.7 ng/μL (SD = 16.9, n = 61 with 16 samples excluded as concentrations exceeded upper detection limit of assay), and rectal swabs was 26.3 ng/μL (SD = 15.5, n = 195 with 25 samples excluded as concentrations exceeded upper detection limit of assay). Only a subset of each sample type assayed for dsDNA concentration.

Appendix 1—figure 2
Enrollment and stool sample collection profile.

Graphs depict 4-week rolling average of the number of intervention and control children enrolled/visited (solid lines) and the number of stool samples collected (including whole stool, diaper samples, and rectal swabs) during the baseline, 12-month, and 24-month phases. The overall success of stool sample collection was 78% at baseline, 86% at 12 month, and 90% at 24 month. The increase in success rate was due to the introduction of rectal swab collection during the 12-month phase.

Appendix 1—figure 3
Distribution of age (years) of enrolled children at each phase.

Results are presented as kernel density plots and stratified by study arm (intervention=blue, control=green) and phase: (a) Baseline phase, (b) 12-month follow-up, (c) 24-month follow-up, and (d) All phases combined.

Appendix 1—table 2
Age stratified baseline prevalence of health outcomes.
Baseline Prevalence
1–11 months12–23 months24–48 months
Any bacterial or protozoan infection
All children108/208 (52%)179/221 (81%)277/297 (93%)
Control57/109 (52%)101/119 (85%)143/152 (94%)
Intervention51/99 (52%)78/102 (76%)134/145 (92%)
Any STH infection
All children30/185 (16%)89/203 (44%)171/277 (62%)
Control17/93 (18%)50/112 (45%)94/144 (65%)
Intervention13/92 (14%)39/91 (43%)77/133 (58%)
Diarrhea
All children37/258 (14%)52/264 (20%)36/427 (8.4%)
Control19/138 (14%)27/146 (18%)20/234 (8.6%)
Intervention18/120 (15%)25/118 (21%)16/193 (8.3%)
Any bacterial infection
All children94/208 (45%)150/221 (68%)229/297 (77%)
Intervention53/109 (49%)89/119 (75%)117/152 (77%)
All children41/99 (41%)61/102 (60%)112/145 (77%)
Shigella
All children19/208 (9.1%)97/221 (44%)192/297 (65%)
Control10/109 (9.2%)57/119 (48%)101/152 (66%)
Intervention9/99 (9.1%)40/102 (39%)91/145 (63%)
ETEC
All children47/208 (23%)81/221 (37%)90/297 (30%)
Control25/109 (23%)45/119 (38%)43/152 (28%)
Intervention22/99 (22%)36/102 (35%)47/145 (32%)
Campylobacter
All children22/208 (11%)19/221 (8.6%)16/297 (5.4%)
Control14/109 (13%)13/119 (11%)10/152 (6.6%)
Intervention8/99 (8.1%)6/102 (5.9%)6/145 (4.1%)
C. difficile
All children23/208 (11%)10/221 (4.5%)2/297 (0.67%)
Control13/109 (12%)7/119 (5.9%)2/152 (1.3%)
Intervention10/99 (10%)3/102 (2.9%)0/145 (0.0%)
E. coli o157
All children6/208 (2.9%)10/221 (4.5%)15/297 (5%)
Control4/109 (3.7%)3/119 (2.5%)6/152 (4%)
Intervention2/99 (2%)7/102 (6.9%)9/145 (6.2%)
STEC
All children3/208 (1.4%)7/221 (3.2%)3/297 (1%)
Control0/109 (0.0%)1/119 (0.84%)2/152 (1.3%)
Intervention3/99 (3%)6/102 (5.9%)1/145 (0.69%)
Y. enterocolitica
All children0/208 (0.0%)1/221 (0.45%)0/297 (0.0%)
Control0/109 (0.0%)0/119 (0.0%)0/152 (0.0%)
Intervention0/99 (0.0%)1/102 (0.98%)0/145 (0.0%)
V. cholerae
All children0/208 (0.0%)0/221 (0.0%)0/297 (0.0%)
Control0/109 (0.0%)0/119 (0.0%)0/152 (0.0%)
Intervention0/99 (0.0%)0/102 (0.0%)0/145 (0.0%)
Any Protozoa
All children36/208 (17%)120/221 (54%)223/297 (75%)
Control14/109 (13%)68/119 (57%)114/152 (75%)
Intervention22/99 (22%)52/102 (51%)109/145 (75%)
Giardia
All children28/208 (13%)119/221 (54%)219/297 (74%)
Control12/109 (11%)67/119 (56%)113/152 (74%)
Intervention16/99 (16%)52/102 (51%)106/145 (73%)
Cryptosporidium
All children10/208 (4.8%)9/221 (4.1%)5/297 (1.7%)
Control2/109 (1.8%)5/119 (4.2%)1/152 (0.66%)
Intervention8/99 (8.1%)4/102 (3.9%)4/145 (2.8%)
E. histolytica
All children1/208 (0.48%)0/221 (0.0%)3/297 (1%)
Control0/109 (0.0%)0/119 (0.0%)0/152 (0.0%)
Intervention1/99 (1%)0/102 (0.0%)3/145 (2.1%)
Any virus
All children36/208 (17%)34/221 (15%)33/297 (11%)
Control15/109 (14%)19/119 (16%)19/152 (13%)
Intervention21/99 (21%)15/102 (15%)14/145 (9.7%)
Norovirus GI/GII
All children27/208 (13%)25/221 (11%)23/297 (7.7%)
Control12/109 (11%)14/119 (12%)12/152 (7.9%)
Intervention15/99 (15%)11/102 (11%)11/145 (7.6%)
Adenovirus 40/41
All children7/208 (3.4%)7/221 (3.2%)8/297 (2.7%)
Control4/109 (3.7%)3/119 (2.5%)6/152 (4%)
Intervention3/99 (3%)4/102 (3.9%)2/145 (1.4%)
Rotavirus A
All children3/208 (1.4%)5/221 (2.3%)2/297 (0.67%)
Control0/109 (0.0%)2/119 (1.7%)1/152 (0.66%)
Intervention3/99 (3%)3/102 (2.9%)1/145 (0.69%)
Coinfection, ≥2 GPP pathogens
All children48/208 (23%)118/221 (53%)203/297 (68%)
Control23/109 (21%)69/119 (58%)104/152 (68%)
Intervention25/99 (25%)49/102 (48%)99/145 (68%)
Trichuris
All children20/185 (11%)69/203 (34%)150/277 (54%)
Control10/93 (11%)38/112 (34%)82/144 (57%)
Intervention10/92 (11%)31/91 (34%)68/133 (51%)
Ascaris
All children21/185 (11%)53/203 (26%)81/277 (29%)
Control12/93 (13%)33/112 (29%)47/144 (33%)
Intervention9/92 (9.8%)20/91 (22%)34/133 (26%)
Coinfection, ≥2 STH
All children11/185 (6%)33/203 (16%)60/277 (22%)
Control5/93 (5.4%)21/112 (19%)35/144 (24%)
Intervention6/92 (6.5%)12/91 (13%)25/133 (19%)
Number of GPP infections
All children0.94 (1.1)1.8 (1.2)1.9 (0.95)
Control0.88 (1.1)1.8 (1.1)2 (0.93)
Intervention1 (1.1)1.7 (1.3)1.9 (0.98)
Number of STH infections
All children0.23 (0.55)0.61 (0.75)0.86 (0.76)
Control0.24 (0.54)0.64 (0.78)0.9 (0.76)
Intervention0.23 (0.56)0.57 (0.72)0.8 (0.76)
  1. Data presented n/N (%) or mean (standard deviation). All bacterial, protozoan, and viral pathogens were measured using the Luminex Gastrointestinal Pathogen panel. STH were measured using the Kato-Katz method. Diarrhea was measured via caregiver report in household surveys.

Appendix 1—figure 4
Prevalence of pathogens by age at baseline, 12-month, and 24-month phases.

Results are smoothed averages stratified by study arm with 95% confidence intervals represented by shaded areas.

Appendix 1—table 3
Baseline enrollment characteristics of children with and without repeated measures at the 12-month phase.

Results are presented for all children combined and stratified by study arm.

All childrenControlIntervention
BL and 12M*BL only†Std. diff.‡BL and 12MBL onlyStd. diff.BL and 12MBL onlyStd. diff.
Outcomes
Diarrhea83/609 (14%)43/365 (12%)0.0638/310 (12%)29/216 (13%)0.0345/299 (15%)14/149 (9.4%)0.17
Any bacterial or protozoan infection376/485 (78%)215/268 (80%)0.07184/234 (79%)129/158 (82%)0.08192/251 (76%)86/110 (78%)0.04
Any GPP infection390/485 (80%)225/268 (84%)0.09188/234 (80%)135/158 (85%)0.14202/251 (80%)90/110 (82%)0.03
Any bacterial infection311/485 (64%)187/268 (70%)0.12157/234 (67%)114/158 (72%)0.11154/251 (61%)73/110 (66%)0.10
Shigella200/485 (41%)131/268 (49%)0.15101/234 (43%)78/158 (49%)0.1299/251 (39%)53/110 (48%)0.18
ETEC147/485 (30%)79/268 (29%)0.0268/234 (29%)48/158 (30%)0.0379/251 (31%)31/110 (28%)0.07
Campylobacter37/485 (7.6%)23/268 (8.6%)0.0322/234 (9.4%)17/158 (11%)0.0515/251 (6%)6/110 (5.5%)0.02
C. difficile23/485 (4.7%)12/268 (4.5%)0.0115/234 (6.4%)7/158 (4.4%)0.098/251 (3.2%)5/110 (4.5%)0.07
E. coli O15719/485 (3.9%)12/268 (4.5%)0.039/234 (3.9%)4/158 (2.5%)0.0710/251 (4%)8/110 (7.3%)0.14
STEC7/485 (1.4%)6/268 (2.2%)0.061/234 (0.43%)2/158 (1.3%)0.096/251 (2.4%)4/110 (3.6%)0.07
Any protozoan infection257/485 (53%)143/268 (53%)0.01126/234 (54%)79/158 (50%)0.08131/251 (52%)64/110 (58%)0.12
Giardia247/485 (51%)140/268 (52%)0.03122/234 (52%)79/158 (50%)0.04125/251 (50%)61/110 (55%)0.11
Cryptosporidium20/485 (4.1%)4/268 (1.5%)0.167/234 (3%)1/158 (0.63%)0.1813/251 (5.2%)3/110 (2.7%)0.13
E. histolytica2/485 (0.41%)2/268 (0.75%)0.040/234 (0.0%)0/158 (0.0%). .**2/251 (0.80%)2/110 (1.8%)0.09
Any viral infection66/485 (14%)39/268 (15%)0.0331/234 (13%)22/158 (14%)0.0235/251 (14%)17/110 (15%)0.04
Adenovirus 40/4114/485 (2.9%)8/268 (3%)0.018/234 (3.4%)5/158 (3.2%)0.016/251 (2.4%)3/110 (2.7%)0.02
Norovirus GI/GII50/485 (10%)27/268 (10%)0.0123/234 (9.8%)15/158 (9.5%)0.0127/251 (11%)12/110 (11%)0.00
Rotavirus A5/485 (1%)5/268 (1.9%)0.071/234 (0.43%)2/158 (1.3%)0.094/251 (1.6%)3/110 (2.7%)0.08
Coinfection, ≥2 GPP infections251/485 (52%)140/268 (52%)0.01126/234 (54%)80/158 (51%)0.06125/251 (50%)60/110 (55%)0.10
Any STH infection202/447 (45%)106/242 (44%)0.03106/218 (49%)64/142 (45%)0.0796/229 (42%)42/100 (42%)0.00
Ascaris109/447 (24%)54/242 (22%)0.0565/218 (30%)30/142 (21%)0.2044/229 (19%)24/100 (24%)0.12
Trichuris170/447 (38%)86/242 (36%)0.0585/218 (39%)54/142 (38%)0.0285/229 (37%)32/100 (32%)0.11
Coinfection,≥2 STH infections77/447 (17%)34/242 (14%)0.0944/218 (20%)20/142 (14%)0.1633/229 (14%)14/100 (14%)0.01
Number of GPP infections1.6 (1.1)1.7 (1.1)0.071.6 (1.1)1.6 (1.1)0.021.6 (1.1)1.7 (1.2)0.14
Number of STH infections0.64 (0.77)0.58 (0.73)0.080.7 (0.79)0.59 (0.73)0.140.59 (0.75)0.57 (0.73)0.03
Child-, household-, compound-level characteristics
Child sex, female319/614 (52%)174/350 (50%)0.04169/312 (54%)97/208 (47%)0.15150/302 (50%)77/142 (54%)0.09
Child breastfed206/609 (34%)106/365 (29%)0.10107/310 (35%)62/216 (29%)0.1399/299 (33%)44/149 (30%)0.08
Child exclusively breastfed51/609 (8.4%)35/365 (9.6%)0.0427/310 (8.7%)22/216 (10%)0.0524/299 (8%)13/149 (8.7%)0.03
Child age at survey, days697 (409)697 (396)0.00698 (409)703 (400)0.01696 (409)689 (391)0.02
Child age at sampling, days668 (399)656 (382)0.03661 (397)655 (395)0.02674 (402)657 (364)0.04
Child wears diapers402/609 (66%)234/364 (64%)0.04209/310 (67%)133/216 (62%)0.12193/299 (65%)101/148 (68%)0.08
Child feces disposed in latrine173/609 (28%)116/365 (32%)0.0779/310 (25%)69/216 (32%)0.1494/299 (31%)47/149 (32%)0.00
Caregiver completed primary school333/614 (54%)193/365 (53%)0.03163/312 (52%)124/216 (57%)0.10170/302 (56%)69/149 (46%)0.20
Mother alive576/590 (98%)353/358 (99%)0.07295/301 (98%)208/212 (98%)0.01281/289 (97%)145/146 (99%)0.16
Respondent is child's mother414/605 (68%)238/357 (67%)0.04222/307 (72%)146/212 (69%)0.08192/298 (64%)92/145 (63%)0.02
Household floors covered575/615 (94%)349/368 (95%)0.06300/313 (96%)211/217 (97%)0.08275/302 (91%)138/151 (91%)0.01
Household walls made of sturdy material399/615 (65%)243/368 (66%)0.02216/313 (69%)154/217 (71%)0.04183/302 (61%)89/151 (59%)0.03
Latrine has drop-hole359/604 (59%)193/364 (53%)0.13169/307 (55%)109/214 (51%)0.08190/297 (64%)84/150 (56%)0.16
Latrine has vent-pipe93/605 (15%)44/364 (12%)0.1021/308 (6.8%)12/214 (5.6%)0.0572/297 (24%)32/150 (21%)0.07
Latrine has ceramic or concrete slab or pedestal224/602 (37%)133/363 (37%)0.01101/305 (33%)80/213 (38%)0.09123/297 (41%)53/150 (35%)0.13
Latrine has sturdy walls193/605 (32%)110/363 (30%)0.0384/306 (27%)58/215 (27%)0.01109/299 (36%)52/148 (35%)0.03
Water tap on compound grounds468/606 (77%)285/364 (78%)0.03224/308 (73%)162/214 (76%)0.07244/298 (82%)123/150 (82%)0.00
Household crowding,≥3 persons/room122/615 (20%)45/368 (12%)0.2155/313 (18%)22/217 (10%)0.2267/302 (22%)23/151 (15%)0.18
Compound electricity normally functions556/615 (90%)331/372 (89%)0.05272/313 (87%)195/220 (89%)0.05284/302 (94%)136/152 (89%)0.17
Standing water observed in compound44/605 (7.3%)26/363 (7.2%)0.007/306 (2.3%)7/215 (3.3%)0.0637/299 (12%)19/148 (13%)0.01
Leaking or standing wastewater observed in compound371/605 (61%)233/363 (64%)0.06214/306 (70%)149/215 (69%)0.01157/299 (53%)84/148 (57%)0.09
Any animal observed395/615 (64%)226/372 (61%)0.07189/313 (60%)129/220 (59%)0.04206/302 (68%)97/152 (64%)0.09
Dog observed51/615 (8.3%)23/372 (6.2%)0.0818/313 (5.8%)10/220 (4.5%)0.0533/302 (11%)13/152 (8.6%)0.08
Chicken or duck observed94/615 (15%)36/372 (9.7%)0.1743/313 (14%)27/220 (12%)0.0451/302 (17%)9/152 (5.9%)0.35
Cat observed341/615 (55%)205/372 (55%)0.01167/313 (53%)120/220 (55%)0.02174/302 (58%)85/152 (56%)0.03
Faeces or used diapers observed around compound276/605 (46%)177/363 (49%)0.06166/306 (54%)116/215 (54%)0.01110/299 (37%)61/148 (41%)0.09
Compound floods during rain377/615 (61%)226/372 (61%)0.01211/313 (67%)137/220 (62%)0.11166/302 (55%)89/152 (59%)0.07
Number of household members6.4 (3.3)5.6 (2.6)0.276 (3)5.2 (2.1)0.336.8 (3.5)6.3 (3.1)0.18
Household wealth score, 0–10.43 (0.1)0.44 (0.099)0.100.44 (0.1)0.45 (0.097)0.150.43 (0.1)0.43 (0.1)0.01
Number of households in compound5.2 (4.6)4.7 (4.4)0.114.4 (2.9)3.8 (1.7)0.216.1 (5.6)6 (6.4)0.02
Compound population21 (15)19 (14)0.1817 (8.1)15 (6.1)0.2226 (18)24 (20)0.11
Number of water taps in compound1.5 (2.2)1.2 (1)0.221 (1.1)0.97 (0.83)0.042.1 (2.8)1.4 (1.2)0.30
Number of latrines/drop-holes in compound1.1 (0.63)1.1 (0.65)0.001 (0.24)1 (0.2)0.041.2 (0.86)1.3 (0.97)0.03
Compound population density0.084 (0.046)0.078 (0.045)0.130.076 (0.04)0.07 (0.039)0.140.092 (0.051)0.089 (0.05)0.06
  1. Results are presented as prevalence (n/N (%)) or mean (standard deviation) at baseline.

    *Prevalence (or mean (SD)) for children with repeated observations at baseline and 12-month visits.

  2. Prevalence (or mean (SD)) for children with observations at baseline visit and not the 12-month visit.

    Standardized mean difference between observations of children with and without repeated measures at baseline and 12-month visits.

  3. § Could not be calculated.

Appendix 1—table 4
Baseline enrollment characteristics of children with and without repeated measures at the 24-month phase.

Results are presented for all children combined and stratified by study arm.

All childrenControlIntervention
BL and 24M*BL onlyStd. Diff.BL and 24MBL onlyStd. Diff.BL and 24MBL onlyStd. Diff.
Outcomes
Diarrhea75/504 (15%)51/470 (11%)0.1235/244 (14%)32/282 (11%)0.0940/260 (15%)19/188 (10%)0.16
Any bacterial or protozoan infection310/394 (79%)281/359 (78%)0.01144/183 (79%)169/209 (81%)0.05166/211 (79%)112/150 (75%)0.09
Any GPP infection322/394 (82%)293/359 (82%)0.00148/183 (81%)175/209 (84%)0.07174/211 (82%)118/150 (79%)0.10
Any bacterial infection251/394 (64%)247/359 (69%)0.11120/183 (66%)151/209 (72%)0.14131/211 (62%)96/150 (64%)0.04
Shigella158/394 (40%)173/359 (48%)0.1674/183 (40%)105/209 (50%)0.2084/211 (40%)68/150 (45%)0.11
ETEC115/394 (29%)111/359 (31%)0.0453/183 (29%)63/209 (30%)0.0362/211 (29%)48/150 (32%)0.06
Campylobacter31/394 (7.9%)29/359 (8.1%)0.0118/183 (9.8%)21/209 (10%)0.0113/211 (6.2%)8/150 (5.3%)0.04
C. difficile18/394 (4.6%)17/359 (4.7%)0.0110/183 (5.5%)12/209 (5.7%)0.018/211 (3.8%)5/150 (3.3%)0.02
E. coli O15717/394 (4.3%)14/359 (3.9%)0.027/183 (3.8%)6/209 (2.9%)0.0510/211 (4.7%)8/150 (5.3%)0.03
STEC6/394 (1.5%)7/359 (1.9%)0.032/183 (1.1%)1/209 (0.48%)0.074/211 (1.9%)6/150 (4%)0.12
Any protozoan infection214/394 (54%)186/359 (52%)0.0596/183 (52%)109/209 (52%)0.01118/211 (56%)77/150 (51%)0.09
Giardia204/394 (52%)183/359 (51%)0.0292/183 (50%)109/209 (52%)0.04112/211 (53%)74/150 (49%)0.08
Cryptosporidium20/394 (5.1%)4/359 (1.1%)0.237/183 (3.8%)1/209 (0.48%)0.2313/211 (6.2%)3/150 (2%)0.21
E. histolytica2/394 (0.51%)2/359 (0.56%)0.010/183 (0.0%)0/209 (0.0%)..§2/211 (0.95%)2/150 (1.3%)0.04
Any viral infection55/394 (14%)50/359 (14%)0.0022/183 (12%)31/209 (15%)0.0833/211 (16%)19/150 (13%)0.09
Adenovirus 40/4114/394 (3.5%)8/359 (2.2%)0.087/183 (3.8%)6/209 (2.9%)0.057/211 (3.3%)2/150 (1.3%)0.13
Norovirus GI/GII42/394 (11%)35/359 (9.8%)0.0315/183 (8.2%)23/209 (11%)0.1027/211 (13%)12/150 (8%)0.16
Rotavirus A3/394 (0.76%)7/359 (1.9%)0.101/183 (0.55%)2/209 (0.96%)0.052/211 (0.95%)5/150 (3.3%)0.17
Coinfection,≥2 GPP infections206/394 (52%)185/359 (52%)0.0297/183 (53%)109/209 (52%)0.02109/211 (52%)76/150 (51%)0.02
Any STH infection156/362 (43%)152/327 (46%)0.0780/171 (47%)90/189 (48%)0.0276/191 (40%)62/138 (45%)0.10
Ascaris85/362 (23%)78/327 (24%)0.0150/171 (29%)45/189 (24%)0.1235/191 (18%)33/138 (24%)0.14
Trichuris128/362 (35%)128/327 (39%)0.0863/171 (37%)76/189 (40%)0.0765/191 (34%)52/138 (38%)0.08
Coinfection,≥2 STH infections57/362 (16%)54/327 (17%)0.0233/171 (19%)31/189 (16%)0.0824/191 (13%)23/138 (17%)0.12
Number of GPP infections1.6 (1.1)1.6 (1.2)0.041.6 (1.1)1.7 (1.1)0.101.6 (1.1)1.6 (1.2)0.01
Number of STH infections0.61 (0.75)0.64 (0.76)0.040.67 (0.78)0.65 (0.75)0.030.55 (0.72)0.63 (0.77)0.10
Child-, household-, compound-level characteristics
Child sex, female260/503 (52%)233/461 (51%)0.02124/241 (51%)142/279 (51%)0.01136/262 (52%)91/182 (50%)0.04
Child breastfed172/504 (34%)140/470 (30%)0.0987/244 (36%)82/282 (29%)0.1485/260 (33%)58/188 (31%)0.04
Child exclusively breastfed35/504 (6.9%)51/470 (11%)0.1419/244 (7.8%)30/282 (11%)0.1016/260 (6.2%)21/188 (11%)0.18
Child age at survey, days698 (403)696 (405)0.01689 (400)709 (410)0.05707 (406)675 (398)0.08
Child age at sampling, days675 (406)651 (379)0.06666 (403)652 (390)0.04682 (409)650 (364)0.08
Child wears diapers343/504 (68%)293/469 (62%)0.12171/244 (70%)171/282 (61%)0.20172/260 (66%)122/187 (65%)0.02
Child feces disposed in latrine138/504 (27%)151/470 (32%)0.1057/244 (23%)91/282 (32%)0.2081/260 (31%)60/188 (32%)0.02
Caregiver completed primary school274/507 (54%)252/472 (53%)0.01131/245 (53%)156/283 (55%)0.03143/262 (55%)96/189 (51%)0.08
Mother alive474/486 (98%)455/462 (98%)0.07232/236 (98%)271/277 (98%)0.03242/250 (97%)184/185 (99%)0.20
Respondent is child's mother337/500 (67%)315/462 (68%)0.02173/241 (72%)195/278 (70%)0.04164/259 (63%)120/184 (65%)0.04
Household floors covered469/507 (93%)455/476 (96%)0.13233/245 (95%)278/285 (98%)0.13236/262 (90%)177/191 (93%)0.09
Household walls made of sturdy material337/507 (66%)305/476 (64%)0.05184/245 (75%)186/285 (65%)0.22153/262 (58%)119/191 (62%)0.08
Latrine has drop-hole294/497 (59%)258/471 (55%)0.09133/239 (56%)145/282 (51%)0.08161/258 (62%)113/189 (60%)0.05
Latrine has vent-pipe80/497 (16%)57/472 (12%)0.1218/239 (7.5%)15/283 (5.3%)0.0962/258 (24%)42/189 (22%)0.04
Latrine has ceramic or concrete slab or pedestal184/494 (37%)173/471 (37%)0.0177/236 (33%)104/282 (37%)0.09107/258 (41%)69/189 (37%)0.10
Latrine has sturdy walls165/501 (33%)138/467 (30%)0.0767/240 (28%)75/281 (27%)0.0398/261 (38%)63/186 (34%)0.08
Water tap on compound grounds389/498 (78%)364/472 (77%)0.02171/239 (72%)215/283 (76%)0.10218/259 (84%)149/189 (79%)0.14
Household crowding,≥3 persons/room114/507 (22%)53/476 (11%)0.3145/245 (18%)32/285 (11%)0.2069/262 (26%)21/191 (11%)0.40
Compound electricity normally functions454/507 (90%)433/480 (90%)0.02214/245 (87%)253/288 (88%)0.02240/262 (92%)180/192 (94%)0.08
Standing water observed in compound39/501 (7.8%)31/467 (6.6%)0.047/240 (2.9%)7/281 (2.5%)0.0332/261 (12%)24/186 (13%)0.02
Leaking or standing wastewater observed in compound308/501 (61%)296/467 (63%)0.04164/240 (68%)199/281 (71%)0.05144/261 (55%)97/186 (52%)0.06
Any animal observed337/507 (66%)284/480 (59%)0.15156/245 (64%)162/288 (56%)0.15181/262 (69%)122/192 (64%)0.12
Dog observed49/507 (9.7%)25/480 (5.2%)0.1717/245 (6.9%)11/288 (3.8%)0.1432/262 (12%)14/192 (7.3%)0.17
Chicken or duck observed71/507 (14%)59/480 (12%)0.0532/245 (13%)38/288 (13%)0.0039/262 (15%)21/192 (11%)0.12
Cat observed294/507 (58%)252/480 (53%)0.11143/245 (58%)144/288 (50%)0.17151/262 (58%)108/192 (56%)0.03
Feces or used diapers observed around compound218/501 (44%)235/467 (50%)0.14120/240 (50%)162/281 (58%)0.1598/261 (38%)73/186 (39%)0.03
Compound floods during rain310/507 (61%)293/480 (61%)0.00166/245 (68%)182/288 (63%)0.10144/262 (55%)111/192 (58%)0.06
Number of household members6.7 (3.4)5.5 (2.6)0.396.3 (3)5.2 (2.2)0.427.1 (3.6)6.1 (3)0.31
Household wealth score, 0–10.43 (0.11)0.44 (0.097)0.120.44 (0.1)0.45 (0.095)0.100.42 (0.11)0.43 (0.1)0.11
Number of households in compound5.3 (4.7)4.7 (4.3)0.134.4 (3.1)3.9 (1.8)0.216.1 (5.7)5.9 (6.2)0.03
Compound population22 (15)18 (14)0.2617 (8.1)15 (6.5)0.2727 (18)23 (19)0.18
Number of water taps in compound1.6 (2.2)1.2 (1.3)0.241 (1)0.99 (0.92)0.022.2 (2.8)1.4 (1.8)0.31
Number of latrines in compound1.1 (0.62)1.1 (0.65)0.011 (0.25)1 (0.19)0.041.2 (0.82)1.3 (0.99)0.08
Compound population density0.084 (0.049)0.079 (0.042)0.130.072 (0.038)0.075 (0.04)0.050.096 (0.055)0.084 (0.044)0.23
  1. Results are presented as prevalence (n/N (%)) or mean (standard deviation) at baseline.

    *Prevalence (or mean (SD)) for children with repeated observations at baseline and 24-month visits.

  2. Prevalence (or mean (SD)) for children with observations at the baseline visit and not the 24-month visit.

    Standardized mean difference between observations of children with and without repeated measures at baseline and 24-month visits.

  3. §Could not be calculated.

Appendix 1—table 5
Balance of characteristics measured at 12-month visits between children with repeat observations at baseline and 12-month and children with observations at the 12-month phase only.
All ChildrenControlIntervention
BL and 12M*12M onlyStd. Diff.BL and 12M12M onlyStd. Diff.BL and 12M12M onlyStd. Diff.Std. Diff. Control v. Interv.§
Child sex, female319/614 (52%)156/313 (50%)0.04169/312 (54%)73/155 (47%)0.14150/302 (50%)83/158 (53%)0.060.11
Child breastfed27/562 (4.8%)161/305 (53%)1.2513/280 (4.6%)76/151 (50%)1.1914/282 (5%)85/154 (55%)1.310.10
Child exclusively breastfed3/562 (0.53%)38/305 (12%)0.502/280 (0.71%)16/151 (11%)0.441/282 (0.35%)22/154 (14%)0.560.11
Caregiver completed primary school305/614 (50%)144/309 (47%)0.06156/312 (50%)62/153 (41%)0.19149/302 (49%)82/156 (53%)0.060.24
Child wears diapers83/563 (15%)194/305 (64%)1.1640/281 (14%)92/151 (61%)1.1043/282 (15%)102/154 (66%)1.210.11
Respondent is child's mother365/563 (65%)236/305 (77%)0.28188/281 (67%)121/151 (80%)0.30177/282 (63%)115/154 (75%)0.260.13
Household floors covered584/615 (95%)305/321 (95%)0.00299/313 (96%)155/163 (95%)0.02285/302 (94%)150/158 (95%)0.030.01
Household walls made of sturdy material398/615 (65%)189/321 (59%)0.12212/313 (68%)101/163 (62%)0.12186/302 (62%)88/158 (56%)0.120.13
Household crowding,≥3 persons/room210/615 (34%)106/321 (33%)0.02111/313 (35%)54/163 (33%)0.0599/302 (33%)52/158 (33%)0.000.00
Compound electricity normally functions575/615 (94%)304/324 (94%)0.01286/313 (91%)152/164 (93%)0.05289/302 (96%)152/160 (95%)0.030.10
Any animal observed505/611 (83%)275/324 (85%)0.06235/309 (76%)131/164 (80%)0.09270/302 (89%)144/160 (90%)0.020.29
Dog observed134/611 (22%)81/324 (25%)0.0757/309 (18%)37/164 (23%)0.1077/302 (26%)44/160 (28%)0.050.11
Chicken or duck observed77/611 (13%)42/324 (13%)0.0134/309 (11%)18/164 (11%)0.0043/302 (14%)24/160 (15%)0.020.12
Cat observed469/611 (77%)249/324 (77%)0.00218/309 (71%)118/164 (72%)0.03251/302 (83%)131/160 (82%)0.030.24
Compound floods during rain220/615 (36%)119/324 (37%)0.02132/313 (42%)64/164 (39%)0.0688/302 (29%)55/160 (34%)0.110.10
Child age at survey, days1114 (415)622 (502)1.071105 (413)684 (535)0.881122 (417)560 (461)1.280.25
Child age at sampling, days1102 (417)605 (484)1.101080 (414)649 (516)0.921122 (420)563 (450)1.290.18
Number of household members6.5 (3.2)6.3 (3.3)0.066.2 (3)6.4 (3.5)0.056.8 (3.3)6.2 (3.2)0.170.05
Household wealth score, 0–10.4 (0.11)0.39 (0.11)0.020.4 (0.11)0.39 (0.11)0.120.39 (0.1)0.4 (0.1)0.100.11
Number of households in compound5.2 (4.7)5.4 (5.5)0.044.2 (2.9)4 (2.3)0.096.3 (5.9)6.9 (7.3)0.090.53
Compound population23 (22)24 (26)0.0418 (9.7)18 (8.7)0.0528 (29)30 (35)0.070.50
Compound population density0.086 (0.049)0.084 (0.051)0.040.08 (0.043)0.078 (0.044)0.050.091 (0.054)0.089 (0.058)0.030.22
  1. Results are presented as prevalence (n/N (%)) or mean (standard deviation) at 12-month visit.

    *Prevalence (or mean (SD)) for children with repeated observations at baseline and 12-month visits.

  2. Prevalence (or mean (SD)) for children with observations at the 12-month visit only.

    Standardized mean difference between observations of children with and without repeated measures at baseline and 12-month visits.

  3. §Standardized mean difference between observations from control and intervention children measured at 12-month visit only.

Appendix 1—table 6
Balance of characteristics measured at 24-month visits between children with repeat observations at baseline and 24-month and children with observations at the 24-month phase only.
All ChildrenControlIntervention
BL and 24M*24M onlyStd. Diff.BL and 24M24M onlyStd. Diff.BL and 24M24M onlyStd. Diff.Std. Diff. Control v. Interv.§
Child sex, female260/503 (52%)190/428 (44%)0.15124/241 (51%)96/222 (43%)0.16136/262 (52%)94/206 (46%)0.130.05
Child breastfed0/418 (0.0%)129/381 (34%)1.010/195 (0.0%)68/194 (35%)1.040/223 (0.0%)61/187 (33%)0.980.05
Child exclusively breastfed0/418 (0.0%)36/381 (9.4%)0.460/195 (0.0%)16/194 (8.3%)0.420/223 (0.0%)20/187 (11%)0.490.08
Caregiver completed primary school199/507 (39%)164/427 (38%)0.0288/245 (36%)82/221 (37%)0.02111/262 (42%)82/206 (40%)0.050.06
Child wears diapers3/419 (0.72%)196/381 (51%)1.421/196 (0.51%)101/194 (52%)1.442/223 (0.9%)95/187 (51%)1.390.03
Respondent is child's mother259/419 (62%)298/381 (78%)0.36129/196 (66%)161/194 (83%)0.40130/223 (58%)137/187 (73%)0.320.24
Household floors covered484/507 (95%)459/467 (98%)0.16237/245 (97%)234/239 (98%)0.07247/262 (94%)225/228 (99%)0.240.06
Household walls made of sturdy material352/507 (69%)296/467 (63%)0.13180/245 (73%)157/239 (66%)0.17172/262 (66%)139/228 (61%)0.100.10
Household crowding,≥3 persons/room137/507 (27%)108/467 (23%)0.0974/245 (30%)66/239 (28%)0.0663/262 (24%)42/228 (18%)0.140.22
Compound electricity normally functions485/507 (96%)472/494 (96%)0.01230/245 (94%)237/254 (93%)0.02255/262 (97%)235/240 (98%)0.040.23
Any animal observed384/507 (76%)359/494 (73%)0.07162/245 (66%)182/254 (72%)0.12222/262 (85%)177/240 (74%)0.270.05
Dog observed70/507 (14%)78/494 (16%)0.0630/245 (12%)40/254 (16%)0.1040/262 (15%)38/240 (16%)0.020.00
Chicken or duck observed63/507 (12%)52/494 (11%)0.0622/245 (9%)32/254 (13%)0.1241/262 (16%)20/240 (8.3%)0.230.14
Cat observed360/507 (71%)340/494 (69%)0.05154/245 (63%)174/254 (69%)0.12206/262 (79%)166/240 (69%)0.220.01
Compound floods during rain182/507 (36%)184/494 (37%)0.0389/245 (36%)107/254 (42%)0.1293/262 (36%)77/240 (32%)0.070.21
Child age at survey, days1518 (407)740 (518)1.671520 (406)749 (541)1.611516 (408)731 (494)1.730.04
Child age at sampling, days1510 (415)694 (478)1.821505 (408)716 (512)1.701516 (422)672 (439)1.960.09
Number of household members6.6 (3.1)6.3 (3.4)0.106.5 (3)6.6 (3.8)0.046.7 (3.1)6 (2.8)0.260.20
Household wealth score, 0–10.41 (0.11)0.41 (0.11)0.010.41 (0.12)0.4 (0.11)0.110.41 (0.1)0.42 (0.097)0.150.19
Number of households in compound5.3 (4.9)5.5 (5.5)0.044.3 (2.8)4.4 (3.2)0.036.2 (6.1)6.6 (6.9)0.060.41
Compound population21 (15)21 (16)0.0418 (9.5)17 (8.9)0.0725 (19)25 (21)0.000.47
Compound population density0.08 (0.047)0.08 (0.047)0.010.074 (0.037)0.075 (0.042)0.030.087 (0.053)0.085 (0.052)0.030.22
  1. Results are presented as prevalence (n/N (%)) or mean (standard deviation) at 24-month visit.

    * Prevalence (or mean (SD)) for children with repeated observations at baseline and 24-month visits.

  2. Prevalence (or mean (SD)) for children with observations at the 24-month visit only.

    Standardized mean difference between observations of children with and without repeated measures at baseline and 24-month visits.

  3. §Standardized mean difference between observations from control and intervention children measured at 24-month visit only.

Appendix 1—table 7
Sensitivity analysis assessing the impact of reported deworming on STH effect estimates 12 and 24 months after the intervention.
12-month Prevalence ratio24-month Prevalence ratio
Main analysis, all children*Adjusted for reported deworming †Restricted to children dewormed at baseline ‡Main analysis, all children*Adjusted for reported deworming †Adjusted for time since deworming§
n = 1239n = 1239n = 1031n = 1161n = 1161N = 1159
Any STH infection1.11 (0.89–1.38)1.09 (0.87–1.35)1.06 (0.84–1.33)0.95 (0.77–1.17)0.93 (0.77–1.16)0.93 (0.75–1.14)
Trichuris1.01 (0.79–1.28)0.98 (0.77–1.24)0.96 (0.74–1.23)0.86 (0.67–1.10)0.85 (0.66–1.08)0.86 (0.67–1.09)
Ascaris1.33 (0.92–1.93)1.30 (0.90–1.88)1.30 (0.87–1.94)0.83 (0.54–1.27)0.84 (0.55–1.29)0.78 (0.51–1.18)
Coinfection,≥2 STH1.17 (0.76–1.79)1.12 (0.73–1.71)1.16 (0.73–1.85)0.63 (0.37–1.07)0.63 (0.37–1.08)0.60 (0.35–1.03)
  1. All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors. All models adjusted for child age, sex, caregiver education level, and household wealth.

    *Analysis includes all children regardless of caregiver-reported deworming status.

  2. †Analysis is adjusted for reported deworming status. Effect estimates at 12 month are adjusted for baseline deworming confirmation, effect estimates at 24 month are adjusted for baseline and/or 12 month deworming confirmation.

    ‡Analysis is restricted to children whose caregivers confirmed baseline deworming.

  3. § Adjusted for time between 12 month deworming and 24 month sample collection, time broken into three intervals: 0–3 months, 4–6 months, and >6 months. The NDC performed 12 month deworming activities at the end of the 12 month phase instead of concurrent to 12 month sample collection resulting in some variation in the amount of time between 12 month deworming and 24 month sample collection among participants. All samples collected during 12 month phase were collected >6 months after deworming and no adjustment for time since deworming was made.

Appendix 1—table 8
Sensitivity analysis assessing impact of independent upgrading of control sanitation facilities on effect estimates.
12-month adjusted prevalence ratio24 month adjusted prevalence ratio
Main analysis, all children*Excluding controls with upgraded sanitation†Main analysis, all children*Excluding controls with upgraded sanitation†
Any bacterial or protozoan infection1.04 (0.94–1.15), n = 15101.05 (0.95–1.16), n = 14910.99 (0.91–1.09), n = 15361.00 (0.91–1.10), n = 1502
Any STH infection1.11 (0.89–1.38), n = 12391.11 (0.89–1.38), n = 12250.95 (0.77–1.17), n = 11610.94 (0.76–1.16), n = 1148
Diarrhea1.69 (0.89–3.21), n = 15941.76 (0.91–3.39), n = 15750.84 (0.47–1.51), n = 15020.81 (0.45–1.48), n = 1471
  1. All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors. All infection outcomes are adjusted for child age and sex, caregiver’s education, and household wealth index, and the diarrhea outcome is also adjusted for baseline presence of a drop-hole cover and reported use of a tap on compound grounds as primary drinking water source.

    * Results represent effect estimates for the main analyses which included control children irrespective of whether their latrines had been independently upgraded (results also presented in Table 2 in main text).

  2. Results from sensitivity analyses which exclude control children living in compounds that independently upgraded their latrines to be similar to the intervention.

Appendix 1—table 9
Confounding assessment for primary outcome and both secondary outcomes (any STH, diarrhea) at 12 months.
n/N (%) or mean (SD) at BaselineStd diff.*Primary outcome UnadjustedPrimary outcome AdjustedAny STH UnadjustedAny STH AdjustedDiarrhea UnadjustedDiarrhea Adjusted
VariableControlInter-vention.Comparator PR: 1.04 (0.94–1.15)Comparator aPR: 1.04 (0.94–1.15)Comparator PR: 1.12 (0.89–1.40)Comparator aPR: 1.11 (0.90–1.38)Comparator PR: 1.41 (0.80–2.48)Comparator aPR: 1.32 (0.75–2.33)
Female266/520 (51%)227/444 (51%)0.001.04 (0.94–1.15)1.04 (0.94–1.15)1.14 (0.91–1.42)1.11 (0.89–1.38)1.39 (0.79–2.46)1.32 (0.75–2.33)
Any breastfeeding169/526 (32%)143/448 (32%)0.001.05 (0.95–1.15)1.05 (0.95–1.15)1.11 (0.90–1.38)1.11 (0.90–1.38)1.39 (0.79–2.45)1.33 (0.75–2.35)
Caregiver completed primary school287/528 (54%)239/451 (53%)0.031.04 (0.94–1.15)1.04 (0.94–1.15)1.12 (0.90–1.41)1.11 (0.89–1.38)1.40 (0.80–2.48)1.32 (0.75–2.33)
Respondent is mother368/519 (71%)284/443 (64%)0.151.05 (0.95–1.16)1.04 (0.94–1.15)1.13 (0.90–1.42)1.11 (0.89–1.38)1.37 (0.78–2.42)1.29 (0.73–2.28)
Household floors covered511/530 (96%)413/453 (91%)0.221.04 (0.94–1.15)1.04 (0.94–1.15)1.12 (0.89–1.40)1.12 (0.90–1.39)1.39 (0.79–2.47)1.32 (0.74–2.34)
Household walls made of sturdy material370/530 (70%)272/453 (60%)0.211.04 (0.94–1.15)1.04 (0.94–1.15)1.12 (0.89–1.40)1.11 (0.89–1.38)1.41 (0.80–2.48)1.32 (0.75–2.33)
Drinking water source in compound386/522 (74%)367/448 (82%)0.191.03 (0.93–1.15)1.03 (0.93–1.14)1.08 (0.85–1.36)1.05 (0.83–1.33)1.65 (0.89–3.06)1.59 (0.85–2.95)
Faeces visible around compound grounds282/521 (54%)171/447 (38%)0.321.03 (0.93–1.13)1.03 (0.93–1.13)1.14 (0.91–1.43)1.12 (0.90–1.40)1.43 (0.81–2.54)1.35 (0.76–2.40)
Compound floods when it rains348/533 (65%)255/454 (56%)0.191.04 (0.94–1.15)1.04 (0.94–1.15)1.12 (0.89–1.40)1.11 (0.89–1.38)1.41 (0.80–2.49)1.32 (0.74–2.33)
Latrine drop-hole has cover278/521 (53%)274/447 (61%)0.161.04 (0.94–1.15)1.03 (0.93–1.15)1.11 (0.88–1.40)1.08 (0.85–1.36)1.74 (0.92–3.30)1.69 (0.89–3.20)
Latrine has ceramic/concrete slab or pedestal181/518 (35%)176/447 (39%)0.091.04 (0.94–1.15)1.04 (0.93–1.15)1.10 (0.87–1.39)1.07 (0.85–1.35)1.71 (0.90–3.24)1.65 (0.87–3.14)
Latrine walls made of sturdy material142/521 (27%)161/447 (36%)0.191.03 (0.93–1.14)1.03 (0.93–1.13)1.14 (0.91–1.43)1.12 (0.90–1.40)1.42 (0.80–2.51)1.33 (0.75–2.37)
Standing water observed around compound14/521 (2.7%)56/447 (13%)0.381.03 (0.93–1.14)1.03 (0.93–1.13)1.14 (0.91–1.42)1.12 (0.90–1.39)1.42 (0.80–2.51)1.34 (0.75–2.38)
Leaking or standing wastewater observed around grounds363/521 (70%)241/447 (54%)0.331.03 (0.93–1.14)1.03 (0.93–1.13)1.14 (0.91–1.43)1.12 (0.90–1.40)1.42 (0.80–2.51)1.34 (0.75–2.38)
Compound has electricity that normally functions467/533 (88%)420/454 (93%)0.161.04 (0.94–1.15)1.04 (0.94–1.15)1.11 (0.89–1.39)1.11 (0.89–1.38)1.41 (0.80–2.48)1.32 (0.75–2.34)
Any animal observed in compound318/533 (60%)303/454 (67%)0.151.04 (0.95–1.15)1.04 (0.95–1.15)1.13 (0.91–1.41)1.13 (0.91–1.40)1.39 (0.79–2.44)1.29 (0.73–2.28)
Dog observed28/533 (5.3%)46/454 (10%)0.181.05 (0.95–1.15)1.04 (0.95–1.15)1.13 (0.90–1.41)1.12 (0.90–1.39)1.38 (0.79–2.40)1.30 (0.75–2.27)
Chicken or duck observed70/533 (13%)60/454 (13%)0.001.05 (0.95–1.15)1.05 (0.95–1.16)1.12 (0.90–1.41)1.12 (0.90–1.40)1.37 (0.78–2.40)1.27 (0.72–2.23)
Cat observed287/533 (54%)259/454 (57%)0.061.05 (0.95–1.16)1.04 (0.95–1.15)1.14 (0.91–1.42)1.13 (0.91–1.41)1.39 (0.79–2.45)1.30 (0.74–2.29)
Compound density, terciles0.401.05 (0.95–1.16)1.05 (0.95–1.16)1.10 (0.88–1.38)1.10 (0.89–1.38)1.43 (0.81–2.50)1.32 (0.75–2.33)
0 (least dense)199/519 (38%)120/447 (27%)..............
1191/519 (37%)137/447 (31%)..............
2 (most dense)129/519 (25%)190/447 (43%)..............
Child age at survey, days700 (405)694 (403)0.02........1.33 (0.76–2.34)1.32 (0.75–2.33)
Child age at sample, days659 (396)669 (391)0.031.04 (0.94–1.14)1.04 (0.94–1.15)1.09 (0.88–1.36)1.11 (0.89–1.38)--
Cumulative monthly rainfall at survey, mm22 (23)23 (24)0.07........1.39 (0.79–2.44)1.30 (0.74–2.29)
Cumulative monthly rainfall at sample, mm25 (30)32 (38)0.191.04 (0.94–1.15)1.04 (0.95–1.15)1.13 (0.90–1.41)1.13 (0.91–1.40)....
Survey collected during rainy season155/526 (29%)222/448 (50%)0.42........1.44 (0.81–2.54)1.34 (0.76–2.38)
Sample collected during rainy season136/409 (33%)183/370 (49%)0.331.05 (0.95–1.16)1.05 (0.95–1.16)1.12 (0.90–1.40)1.12 (0.90–1.39)....
Wealth score0.44 (0.1)0.43 (0.1)0.161.04 (0.94–1.15)1.04 (0.94–1.15)1.12 (0.90–1.40)1.11 (0.89–1.38)1.39 (0.79–2.46)1.32 (0.75–2.33)
Number of household residents5.7 (2.7)6.6 (3.4)0.321.04 (0.94–1.15)1.04 (0.94–1.15)1.13 (0.90–1.41)1.12 (0.90–1.39)1.38 (0.78–2.44)1.31 (0.74–2.31)
Number of Compound residents16 (7.3)25 (19)0.641.04 (0.94–1.15)1.04 (0.94–1.15)1.10 (0.88–1.37)1.09 (0.88–1.35)1.39 (0.79–2.45)1.31 (0.74–2.32)
Number of households in compound4.1 (2.5)6.1 (5.9)0.421.04 (0.94–1.15)1.04 (0.94–1.15)1.11 (0.89–1.37)1.09 (0.88–1.36)1.40 (0.79–2.46)1.31 (0.74–2.32)
Number of compound latrines1.0 (0.22)1.2 (0.9)0.331.04 (0.94–1.15)1.04 (0.94–1.15)1.13 (0.91–1.40)1.12 (0.90–1.39)1.40 (0.79–2.47)1.33 (0.75–2.35)
Number of compound waterpoints0.99 (0.98)1.9 (2.4)0.471.03 (0.93–1.14)1.03 (0.93–1.14)1.13 (0.91–1.42)1.12 (0.90–1.39)1.45 (0.82–2.56)1.37 (0.77–2.43)
  1. *Standardized difference between arms in baseline covariates. † Compared with 12-month unadjusted prevalence ratio (12 month difference-in-difference estimator). ‡ Compared with 12-month prevalence ratio adjusted for a priori covariates child age, sex, caregiver education, and poverty (wealth score).

Appendix 1—table 10
Effect estimates (prevalence ratios) for main analyses and all sub-group analyses adjusted for a priori covariates and age-squared.
Main analysis, all children†Sub-group analysis, children born after intervention*Sub-group analysis, children with repeated (longitudinal) measurements†Age stratified, children aged > 24 months old‡
12 month24 month12 month24 month12 month24 month24 month
Any bacterial or protozoan infection1.05 (0.96–1.15), p=0.291.00 (0.92–1.09), p=0.970.95 (0.64–1.42), p=0.810.97 (0.79–1.18), p=0.731.02 (0.91–1.14), p=0.730.99 (0.89–1.11), p=0.890.98 (0.91–1.05), p=0.57
Any STH infection1.16 (0.93–1.43), p=0.180.94 (0.77–1.15), p=0.541.38 (0.35–5.44), p=0.650.48 (0.26–0.92), p=0.0261.20 (0.91–1.59), p=0.201.22 (0.85–1.75), p=0.271.04 (0.83–1.32), p=0.72
Diarrhea1.73 (0.91–3.28), p=0.0940.84 (0.46–1.51), p=0.551.66 (0.32–8.68), p=0.551.32 (0.45–3.90), p=0.611.71 (0.79–3.71), p=0.170.68 (0.31–1.48), p=0.330.82 (0.36–1.87), p=0.64
Any Bacteria1.10 (0.96–1.26), p=0.151.01 (0.88–1.16), p=0.871.23 (0.75–2.02), p=0.420.88 (0.66–1.16), p=0.371.02 (0.86–1.20), p=0.851.02 (0.85–1.22), p=0.850.96 (0.84–1.11), p=0.61
Shigella1.14 (0.94–1.38), p=0.180.97 (0.81–1.16), p=0.750.87 (0.25–3.02), p=0.830.48 (0.28–0.84), p=0.0091.09 (0.87–1.35), p=0.470.96 (0.75–1.23), p=0.761.02 (0.85–1.23), p=0.82
ETEC0.97 (0.70–1.35), p=0.860.83 (0.57–1.20), p=0.320.80 (0.33–1.95), p=0.630.84 (0.47–1.49), p=0.550.86 (0.58–1.29), p=0.470.86 (0.52–1.40), p=0.530.75 (0.47–1.20), p=0.23
Campylobacter1.70 (0.83–3.49), p=0.151.29 (0.63–2.64), p=0.492.67 (0.59–12.00), p=0.21.63 (0.59–4.54), p=0.351.51 (0.60–3.76), p=0.381.52 (0.60–3.83), p=0.380.98 (0.30–3.21), p=0.97
C. difficile2.06 (0.76–5.53), p=0.151.38 (0.45–4.20), p=0.571.42 (0.43–4.65), p=0.571.45 (0.40–5.25), p=0.571.35 (0.23–7.78), p=0.740.23 (0.02–2.67), p=0.24..‡
E. coli O1570.47 (0.18–1.23), p=0.130.52 (0.17–1.59), p=0.250.00 (0.00–0.01), p=0.000.52 (0.07–4.14), p=0.540.68 (0.22–2.07), p=0.500.58 (0.12–2.86), p=0.510.48 (0.13–1.78), p=0.27
STEC0.15 (0.03–0.71), p=0.0170.24 (0.06–1.03), p=0.055..‡0.05 (0.00–1.26), p=0.0690.11 (0.01–1.32), p=0.0820.58 (0.07–5.00), p=0.621.70 (0.14–20.35), p=0.67
Y. enterocolitica..‡..‡..‡..‡..‡..‡..‡
V. cholerae..‡..‡..‡..‡..‡..‡..‡
Any Protozoa1.05 (0.89–1.23), p=0.60.92 (0.78–1.09), p=0.340.42 (0.14–1.26), p=0.120.86 (0.60–1.23), p=0.411.20 (0.97–1.48), p=0.0950.92 (0.73–1.16), p=0.490.94 (0.80–1.10), p=0.45
Giardia1.07 (0.91–1.26), p=0.430.95 (0.80–1.12), p=0.510.46 (0.15–1.47), p=0.190.89 (0.62–1.28), p=0.521.19 (0.96–1.47), p=0.110.92 (0.73–1.16), p=0.470.96 (0.81–1.13), p=0.6
Cryptosporidium0.89 (0.24–3.33), p=0.860.53 (0.13–2.17), p=0.380.33 (0.02–6.28), p=0.460.51 (0.09–2.78), p=0.441.46 (0.21–10.18), p=0.70.59 (0.06–5.45), p=0.640.20 (0.02–2.28), p=0.19
E. histolytica..‡..‡..‡..‡..‡..‡..‡
Any virus0.75 (0.44–1.28), p=0.291.03 (0.57–1.86), p=0.920.37 (0.14–1.03), p=0.0560.79 (0.35–1.78), p=0.571.09 (0.52–2.29), p=0.830.95 (0.41–2.19), p=0.911.44 (0.61–3.38), p=0.41
Norovirus GI/GII0.68 (0.36–1.28), p=0.231.10 (0.55–2.18), p=0.790.42 (0.12–1.41), p=0.161.25 (0.47–3.29), p=0.660.86 (0.37–2.00), p=0.730.74 (0.29–1.90), p=0.531.16 (0.45–3.04), p=0.76
Adenovirus 40/411.26 (0.32–4.95), p=0.740.96 (0.18–5.20), p=0.960.85 (0.09–8.30), p=0.89..‡3.77 (0.48–29.56), p=0.216.17 (0.51–75.19), p=0.157.51 (0.72–77.98), p=0.091
Rotavirus A..‡..‡..‡..‡..‡..‡..‡
Coinfection,≥2 GPP pathogens1.10 (0.93–1.30), p=0.270.94 (0.80–1.11), p=0.490.75 (0.33–1.71), p=0.490.83 (0.58–1.17), p=0.291.15 (0.93–1.42), p=0.190.97 (0.78–1.21), p=0.810.93 (0.78–1.11), p=0.44
Trichuris1.05 (0.83–1.32), p=0.680.85 (0.67–1.08), p=0.170.99 (0.23–4.27), p=0.980.24 (0.10–0.60), p=0.0021.11 (0.80–1.52), p=0.541.14 (0.76–1.70), p=0.540.99 (0.77–1.27), p=0.92
Ascaris1.38 (0.95–1.99), p=0.0880.83 (0.54–1.26), p=0.373.11 (0.30–32.54), p=0.340.65 (0.29–1.47), p=0.31.20 (0.76–1.92), p=0.430.86 (0.42–1.75), p=0.680.86 (0.51–1.44), p=0.56
Coinfection,≥2 STH1.21 (0.78–1.85), p=0.390.62 (0.37–1.06), p=0.0791.76 (0.15–21), p=0.660.12 (0.01–1.06), p=0.0571.01 (0.53–1.93), p=0.970.70 (0.30–1.62), p=0.400.72 (0.40–1.29), p=0.27
  1. All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors. All models are adjusted for a priori covariates (age, sex, wealth, caregiver education) and age squared to assess the impact of the age squared term on effect estimates. †Results from main analyses examining intervention effects among all enrolled children at 12 month and 24 month visits. Effect estimates compared with 12 month and 24 month results in Table 2.

    *Results from sub-group analyses which compared children born after the intervention was implemented with children of a similar age at baseline. Effect estimates compared with results in Table 3 (24 month sub-group analysis results) and Appendix 1—table 13 (12 month sub-group analysis results).

  2. † Results from sub-group analyses including children with repeated measures at baseline and the 12 month phase or baseline and the 24 month phase. Effect estimates compared with results in Appendix 1—tables 14 and 15.

    ‡ Results from sub-group analysis comparing children aged >2 years old at baseline and 24 month phase. Effect estimates compared with results in Appendix 1—table 12.

Appendix 1—table 11
Comparison of effect estimates (prevalence ratios) at 12- and 24-month adjusted for a priori covariates only and for a priori covariates and seasonality.
12-month prevalence ratio (95% CI)24-month prevalence ratio (95% CI)
Adjusted (a priori only)*Adjusted + seasonality†Adjusted (a priori only)*Adjusted + seasonality†
Any bacterial or protozoan infection1.04 (0.94–1.15), p=0.411.05 (0.95–1.15), p=0.370.99 (0.91–1.09), p=0.891.00 (0.91–1.10), p=0.95
Any STH infection1.11 (0.89–1.38), p=0.351.12 (0.90–1.39), p=0.310.95 (0.77–1.17), p=0.620.94 (0.76–1.15), p=0.54
Diarrhea1.69 (0.89–3.21), p=0.111.67 (0.88–3.17), p=0.120.84 (0.47–1.51), p=0.560.81 (0.44–1.46), p=0.48
Any bacteria1.09 (0.95–1.26), p=0.201.10 (0.96–1.26), p=0.181.00 (0.87–1.15), p=0.951.03 (0.89–1.18), p=0.71
Shigella1.12 (0.92–1.38), p=0.271.12 (0.91–1.37), p=0.280.95 (0.79–1.16), p=0.640.97 (0.80–1.17), p=0.72
ETEC0.96 (0.69–1.33), p=0.810.98 (0.70–1.35), p=0.890.83 (0.57–1.19), p=0.310.88 (0.61–1.26), p=0.47
Campylobacter1.68 (0.82–3.45), p=0.161.72 (0.84–3.49), p=0.141.28 (0.62–2.62), p=0.51.33 (0.65–2.71), p=0.43
C. difficile2.09 (0.77–5.64), p=0.152.17 (0.81–5.86), p=0.131.41 (0.46–4.30), p=0.541.44 (0.48–4.37), p=0.52
E. coli O1570.46 (0.18–1.21), p=0.120.48 (0.18–1.26), p=0.140.52 (0.17–1.59), p=0.250.57 (0.19–1.74), p=0.32
STEC0.15 (0.03–0.70), p=0.0160.15 (0.03–0.74), p=0.0190.24 (0.05–1.01), p=0.0520.25 (0.06–1.06), p=0.061
Y. enterocolitica..‡..‡..‡..‡
V. cholerae..‡..‡..‡..‡
Any Protozoa1.03 (0.86–1.22), p=0.761.03 (0.87–1.23), p=0.720.91 (0.76–1.09), p=0.290.91 (0.76–1.09), p=0.31
Giardia1.05 (0.88–1.25), p=0.581.06 (0.88–1.26), p=0.540.93 (0.78–1.11), p=0.430.93 (0.78–1.12), p=0.45
Cryptosporidium0.89 (0.24–3.31), p=0.860.83 (0.22–3.11), p=0.780.53 (0.13–2.14), p=0.370.46 (0.12–1.73), p=0.25
E. histolytica..‡..‡..‡..‡
Any virus0.75 (0.44–1.27), p=0.290.74 (0.43–1.26), p=0.261.03 (0.57–1.86), p=0.920.97 (0.54–1.75), p=0.91
Norovirus GI/GII0.68 (0.36–1.27), p=0.230.67 (0.35–1.27), p=0.221.10 (0.55–2.18), p=0.791.04 (0.53–2.07), p=0.90
Adenovirus 40/411.24 (0.32–4.83), p=0.761.29 (0.33–5.13), p=0.710.97 (0.18–5.19), p=0.971.01 (0.19–5.30), p=0.99
Rotavirus..‡..‡..‡..‡
Coinfection,≥2 GPP pathogens1.08 (0.91–1.29), p=0.371.09 (0.91–1.30), p=0.350.93 (0.79–1.10), p=0.410.94 (0.79–1.12), p=0.49
Trichuris1.01 (0.79–1.28), p=0.961.02 (0.81–1.30), p=0.860.86 (0.67–1.10), p=0.220.85 (0.67–1.09), p=0.21
Ascaris1.33 (0.92–1.93), p=0.131.35 (0.93–1.95), p=0.110.83 (0.54–1.27), p=0.390.81 (0.53–1.25), p=0.34
Coinfection,≥2 STH1.17 (0.76–1.79), p=0.491.20 (0.78–1.83), p=0.400.63 (0.37–1.07), p=0.0840.62 (0.36–1.06), p=0.079
  1. All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors.

    *Models are adjusted for a priori covariates age, sex, caregiver’s education, and wealth and presented for comparison with seasonality-adjusted models.

  2. †Models are adjusted for a priori covariates and seasonality using sine/cosine terms based on the date of sample (or survey) collection.

Appendix 1—table 12
Effect of the intervention on enteric infection and diarrhea in children > 2 years old after 24 months.
PrevalencePrevalence ratio (95% CI), p-value
Baseline, aged > 2 years24 month, aged > 2 yearsUnadjustedAdjusted*
Any bacterial or protozoan infection†
Control155/164 (95%)315/340 (93%)....
Intervention149/160 (93%)312/344 (91%)0.99 (0.93–1.07), p=0.860.98 (0.91–1.05), p=0.60
Any STH infection†
Control103/155 (66%)113/175 (65%)....
Intervention86/146 (59%)121/208 (58%)1.03 (0.82–1.30), p=0.791.05 (0.83–1.32), p=0.69
Diarrhea‡
Control21/243 (8.6%)33/273 (12%)....
Intervention16/210 (7.6%)31/303 (10%)0.96 (0.45–2.07), p=0.930.82 (0.36–1.86), p=0.63
Any Bacteria
Control129/164 (79%)267/340 (79%)....
Intervention125/160 (78%)266/344 (77%)1.00 (0.87–1.15), p=0.980.97 (0.84–1.11), p=0.64
Shigella
Control112/164 (68%)227/340 (67%)....
Intervention103/160 (64%)223/344 (65%)1.05 (0.87–1.26), p=0.631.03 (0.85–1.24), p=0.79
ETEC
Control46/164 (28%)93/340 (27%)....
Intervention52/160 (33%)100/344 (29%)0.88 (0.56–1.38), p=0.580.74 (0.46–1.20), p=0.22
Campylobacter
Control12/164 (7.3%)33/340 (9.7%)....
Intervention7/160 (4.4%)20/344 (5.8%)0.97 (0.33–2.90), p=0.961.00 (0.30–3.28), p=0.99
C. difficile
Control2/164 (1.2%)6/340 (1.8%)....
Intervention0/160 (0.0%)4/344 (1.2%)..‡..‡
E. coli O157
Control6/164 (3.7%)21/340 (6.2%)....
Intervention9/160 (5.6%)13/344 (3.8%)0.39 (0.11–1.40), p=0.150.47 (0.13–1.78), p=0.27
STEC
Control2/164 (1.2%)15/340 (4.4%)....
Intervention1/160 (0.63%)13/344 (3.8%)1.54 (0.12–19.19), p=0.741.73 (0.14–20.75), p=0.67
Y. enterocolitica
Control0/164 (0.0%)0/340 (0.0%)....
Intervention0/160 (0.0%)1/344 (0.29%)..‡..‡
V. cholerae
Control0/164 (0.0%)0/340 (0.0%)....
Intervention0/160 (0.0%)0/344 (0.0%)..‡..‡
Any Protozoa
Control123/164 (75%)250/340 (74%)....
Intervention121/160 (76%)245/344 (71%)0.96 (0.82–1.13), p=0.660.94 (0.80–1.11), p=0.47
Giardia
Control122/164 (74%)244/340 (72%)....
Intervention118/160 (74%)240/344 (70%)0.99 (0.84–1.16), p=0.860.96 (0.81–1.13), p=0.62
Cryptosporidium
Control1/164 (0.61%)9/340 (2.6%)....
Intervention4/160 (2.5%)8/344 (2.3%)0.20 (0.02–2.27), p=0.190.21 (0.02–2.46), p=0.21
E. histolytica
Control0/164 (0.0%)2/340 (0.59%)....
Intervention3/160 (1.9%)10/344 (2.9%)..‡..‡
Any virus
Control19/164 (12%)39/340 (11%)....
Intervention16/160 (10%)43/344 (13%)1.24 (0.55–2.78), p=0.61.44 (0.61–3.38), p=0.41
Norovirus GI/GII
Control12/164 (7.3%)34/340 (10%)....
Intervention13/160 (8.1%)37/344 (11%)0.96 (0.39–2.34), p=0.921.17 (0.45–3.03), p=0.75
Adenovirus 40/41
Control6/164 (3.7%)2/340 (0.59%)....
Intervention2/160 (1.3%)6/344 (1.7%)11 (0.97–119), p=0.0537.5 (0.72–79), p=0.92
Rotavirus A
Control1/164 (0.61%)3/340 (0.88%)....
Intervention1/160 (0.63%)1/344 (0.29%)..‡..‡
Coinfection,≥2 GPP pathogens
Control114/164 (70%)243/340 (71%)....
Intervention111/160 (69%)236/344 (69%)0.97 (0.82–1.15), p=0.710.93 (0.78–1.12), p=0.45
Trichuris
Control91/155 (59%)102/175 (58%)....
Intervention76/146 (52%)110/208 (53%)1.04 (0.81–1.33), p=0.780.99 (0.77–1.27), p=0.96
Ascaris
Control50/155 (32%)61/175 (35%)....
Intervention39/146 (27%)47/208 (23%)0.78 (0.47–1.29), p=0.330.86 (0.51–1.44), p=0.57
Coinfection,≥2 STH
Control38/155 (25%)50/175 (29%)....
Intervention29/146 (20%)36/208 (17%)0.74 (0.42–1.28), p=0.280.72 (0.41–1.29), p=0.27
  1. Analysis includes children >2 year old at baseline or the 24 month visit. Prevalence results are presented as (n/N (%)). All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors.

    * Pathogen outcomes adjusted for child age and sex, caregiver’s education, and household wealth index, reported diarrhea also adjusted for baseline presence of a drop-hole cover and reported use of a tap on compound grounds as primary drinking water source.

  2. † Models did not converge due to sparse data.

Appendix 1—table 13
Effect of intervention on enteric infection and reported diarrhea in children born into study sites post implementation (post-baseline) and before 12 month visit compared with children of a similar age at baseline (<1 year old).
PrevalencePrevalence ratio
Baseline, children < 1 year old12 month, children born-in and <1 year oldunadjustedadjusted†
Any bacterial or protozoan infection
Control57/109 (52%)31/48 (65%)....
Intervention51/99 (52%)32/55 (58%)0.89 (0.60–1.33), p=0.580.97 (0.65–1.45), p=0.90
Any STH infection
Control17/93 (18%)3/25 (12%)....
Intervention13/92 (14%)4/32 (13%)1.31 (0.32–5.42), p=0.711.38 (0.35–5.45), p=0.65
Diarrhea
Control19/138 (14%)6/50 (12%)....
Intervention18/120 (15%)13/69 (19%)1.38 (0.47–4.01), p=0.561.80 (0.35–9.31), p=0.48
Any Bacteria
Control53/109 (49%)24/48 (50%)....
Intervention41/99 (41%)29/55 (53%)1.22 (0.75–1.98), p=0.431.28 (0.78–2.10), p=0.33
Shigella
Control10/109 (9.2%)9/48 (19%)....
Intervention9/99 (9.1%)9/55 (16%)0.87 (0.26–2.91), p=0.820.85 (0.26–2.81), p=0.79
ETEC
Control25/109 (23%)12/48 (25%)....
Intervention22/99 (22%)11/55 (20%)0.82 (0.34–1.99), p=0.660.80 (0.33–1.92), p=0.62
Campylobacter
Control14/109 (13%)4/48 (8.3%)....
Intervention8/99 (8.1%)5/55 (9.1%)1.76 (0.38–8.09), p=0.472.68 (0.59–12.2), p=0.20
C. difficile
Control13/109 (12%)7/48 (15%)....
Intervention10/99 (10%)9/55 (16%)1.37 (0.42–4.45), p=0.601.49 (0.46–4.89), p=0.51
E. coli O157
Control4/109 (3.7%)1/48 (2.1%)....
Intervention2/99 (2%)0/55 (0.0%)0.01 (0.00–0.19), p=0.001..‡
STEC
Control0/109 (0.0%)0/48 (0.0%)....
Intervention3/99 (3%)1/55 (1.8%)..‡..‡
Y. enterocolitica
Control0/109 (0.0%)0/48 (0.0%)....
Intervention0/99 (0.0%)0/55 (0.0%)..‡..‡
V. cholerae
Control0/109 (0.0%)0/48 (0.0%)....
Intervention0/99 (0.0%)0/55 (0.0%)..‡..‡
Any Protozoa
Control14/109 (13%)15/48 (31%)....
Intervention22/99 (22%)9/55 (16%)0.35 (0.12–1.02), p=0.0550.40 (0.13–1.20), p=0.10
Giardia
Control12/109 (11%)13/48 (27%)....
Intervention16/99 (16%)8/55 (15%)0.41 (0.13–1.24), p=0.110.44 (0.14–1.40), p=0.17
Cryptosporidium
Control2/109 (1.8%)2/48 (4.2%)....
Intervention8/99 (8.1%)2/55 (3.6%)0.25 (0.02–3.70), p=0.310.40 (0.02–7.9), p=0.55
E. histolytica
Control0/109 (0.0%)1/48 (2.1%)....
Intervention1/99 (1%)0/55 (0.0%)..‡..‡
Any virus
Control15/109 (14%)12/48 (25%)....
Intervention21/99 (21%)7/55 (13%)0.33 (0.12–0.92), p=0.0330.37 (0.14–1.03), p=0.056
Norovirus GI/GII
Control12/109 (11%)9/48 (19%)....
Intervention15/99 (15%)6/55 (11%)0.43 (0.13–1.40), p=0.160.44 (0.13–1.47), p=0.18
Adenovirus 40/41
Control4/109 (3.7%)4/48 (8.3%)....
Intervention3/99 (3%)2/55 (3.6%)0.56 (0.06–5.05), p=0.610.91 (0.09–9.49), p=0.94
Rotavirus A
Control0/109 (0.0%)0/48 (0.0%)....
Intervention3/99 (3%)0/55 (0.0%)..‡..‡
Coinfection,≥2 GPP pathogens
Control23/109 (21%)16/48 (33%)....
Intervention25/99 (25%)15/55 (27%)0.73 (0.31–1.71), p=0.470.74 (0.33–1.69), p=0.48
Trichuris
Control10/93 (11%)3/25 (12%)....
Intervention10/92 (11%)4/32 (13%)1.04 (0.21–5.01), p=0.960.98 (0.23–4.29), p=0.98
Ascaris
Control12/93 (13%)1/25 (4%)....
Intervention9/92 (9.8%)3/32 (9.4%)2.87 (0.30–27.85), p=0.363.10 (0.30–32.5), p=0.35
Coinfection,≥2 STH
Control5/93 (5.4%)1/25 (4%)....
Intervention6/92 (6.5%)3/32 (9.4%)1.90 (0.16–22.73), p=0.611.76 (0.15–21.0), p=0.66
  1. Analysis includes children < 1 year old at baseline and children born into the study after baseline and <1 year old at the time of the 12-month visit. Prevalence results are presented as (n/N (%)). All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors.

    *Pathogen outcomes adjusted for child age and sex, caregiver’s education, and household wealth index, reported diarrhea also adjusted for baseline presence of a drop-hole cover and reported use of a tap on compound grounds as primary drinking water source.

  2. † Models did not converge due to sparse data.

Appendix 1—table 14
Effect of the intervention on children with repeated observations at baseline and 12-month visit.
PrevalencePrevalence ratio
Baseline12 monthUnadjustedAdjusted†
Any bacterial or protozoan infection
Control161/207 (78%)187/207 (90%)....
Intervention174/228 (76%)207/228 (91%)1.02 (0.91–1.16), p=0.701.01 (0.90–1.14), p=0.84
Any STH infection
Control67/132 (51%)80/132 (61%)....
Intervention63/154 (41%)91/154 (59%)1.22 (0.92–1.61), p=0.171.16 (0.87–1.55), p=0.31
Diarrhea
Control36/277 (13%)17/277 (6.1%)....
Intervention42/279 (15%)34/279 (12%)1.71 (0.78–3.77), p=0.181.71 (0.79–3.70), p=0.17
Any Bacteria
Control141/207 (68%)165/207 (80%)....
Intervention142/228 (62%)170/228 (75%)1.02 (0.86–1.22), p=0.81.01 (0.85–1.20), p=0.92
Shigella
Control89/207 (43%)128/207 (62%)
Intervention90/228 (39%)142/228 (62%)1.10 (0.86–1.39), p=0.451.08 (0.85–1.37), p=0.54
ETEC
Control63/207 (30%)83/207 (40%)
Intervention71/228 (31%)79/228 (35%)0.84 (0.56–1.27), p=0.410.85 (0.57–1.28), p=0.44
Campylobacter
Control20/207 (9.7%)18/207 (8.7%)
Intervention13/228 (5.7%)18/228 (7.9%)1.54 (0.62–3.80), p=0.351.49 (0.60–3.71), p=0.39
C. difficile
Control15/207 (7.3%)4/207 (1.9%)
Intervention8/228 (3.5%)3/228 (1.3%)1.39 (0.24–8.00), p=0.711.45 (0.25–8.52), p=0.68
E. coli O157
Control9/207 (4.3%)15/207 (7.3%)....
Intervention9/228 (4.0%)10/228 (4.4%)0.67 (0.22–2.03), p=0.480.68 (0.22–2.06), p=0.49
STEC
Control1/207 (0.48%)6/207 (2.9%)....
Intervention6/228 (2.6%)4/227 (1.8%)0.11 (0.01–1.31), p=0.0810.11 (0.01–1.32), p=0.082
Y. enterocolitica
Control0/207 (0.0%)0/207 (0.0%)....
Intervention1/228 (0.44%)0/227 (0.0%)..‡..‡
V. cholerae
Control0/207 (0.0%)0/207 (0.0%)....
Intervention0/228 (0.0%)0/227 (0.0%)..‡..‡
Any Protozoa
Control109/207 (53%)130/207 (63%)....
Intervention117/228 (51%)166/228 (73%)1.19 (0.95–1.48), p=0.131.18 (0.94–1.47), p=0.15
Giardia
Control106/207 (51%)130/207 (63%)
Intervention113/228 (50%)164/228 (72%)1.18 (0.94–1.48), p=0.151.17 (0.93–1.47), p=0.17
Cryptosporidium
Control6/207 (2.9%)2/207 (0.97%)....
Intervention10/228 (4.4%)5/227 (2.2%)1.44 (0.21–9.82), p=0.711.45 (0.22–9.71), p=0.7
E. histolytica
Control0/207 (0.0%)0/207 (0.0)....
Intervention2/228 (0.88%)7/228 (3.1%)..‡..‡
Any virus
Control27/207 (13%)20/207 (9.7%)....
Intervention31/228 (14%)25/228 (11%)1.05 (0.50–2.22), p=0.891.08 (0.51–2.26), p=0.84
Norovirus GI/GII
Control20/207 (9.7%)19/207 (9.2%)
Intervention23/228 (11%)19/228 (8.3%)0.83 (0.36–1.94), p=0.670.86 (0.37–1.99), p=0.72
Adenovirus 40/41
Control7/207 (3.4%)2/207 (0.97%)....
Intervention6/228 (2.6%)6/228 (2.6%)3.56 (0.46–27.24), p=0.223.59 (0.46–27.91), p=0.22
Rotavirus A
Control1/207 (0.48%)1/207 (0.48%)....
Intervention4/228 (1.8%)1/228 (0.44%)..‡..‡
Coinfection,≥2 GPP pathogens
Control114/207 (55%)135/207 (65%)....
Intervention115/228 (50%)156/228 (68%)1.15 (0.92–1.43), p=0.231.14 (0.91–1.42), p=0.25
Trichuris
Control49/132 (37%)64/132 (48%)....
Intervention53/154 (34%)77/154 (50%)1.12 (0.81–1.54), p=0.501.06 (0.76–1.48), p=0.72
Ascaris
Control40/132 (30%)46/132 (35%)
Intervention35/154 (23%)49/154 (32%)1.22 (0.77–1.93), p=0.41.17 (0.73–1.86), p=0.51
Coinfection,≥2 STH
Control22/132 (17%)30/132 (23%)....
Intervention25/154 (16%)35/154 (23%)1.03 (0.55–1.93), p=0.940.97 (0.51–1.85), p=0.93
  1. Analysis includes children with complete observations at baseline and 12-month visits. Prevalence results are presented as (n/N (%)). All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors.

    * Pathogen outcomes adjusted for child age and sex, caregiver’s education, and household wealth index, reported diarrhea also adjusted for baseline presence of a drop-hole cover and reported use of a tap on compound grounds as primary drinking water source.

  2. † Models would not converge due to sparse data.

Appendix 1—table 15
Effect of the intervention on children with repeated observations at baseline and 24-month visit.
PrevalencePrevalence ratio
Baseline24 monthUnadjustedAdjusted†
Any bacterial or protozoan infection
Control131/166 (79%)155/166 (93%)....
Intervention151/192 (79%)175/192 (91%)0.98 (0.87–1.10), p=0.730.98 (0.87–1.10), p=0.70
Any STH infection
Control48/95 (51%)65/95 (68%)....
Intervention38/106 (36%)62/106 (58%)1.20 (0.84–1.70), p=0.311.25 (0.87–1.78), p=0.23
Diarrhea
Control25/196 (13%)20/196 (10%)....
Intervention34/221 (15%)20/221 (9.1%)0.72 (0.33–1.58), p=0.410.69 (0.31–1.50), p=0.35
Any Bacteria
Control109/166 (66%)138/166 (83%)....
Intervention120/192 (63%)153/192 (80%)1.00 (0.84–1.21), p=0.961.01 (0.83–1.21), p=0.96
Shigella
Control66/166 (40%)121/166 (73%)
Intervention79/192 (41%)136/192 (71%)0.93 (0.71–1.22), p=0.600.93 (0.71–1.22), p=0.60
ETEC
Control47/166 (28%)47/166 (28%)
Intervention58/192 (30%)52/192 (27%)0.90 (0.55–1.46), p=0.660.85 (0.52–1.39), p=0.52
Campylobacter
Control16/166 (9.6%)12/166 (7.2%)
Intervention13/192 (6.8%)14/192 (7.3%)1.44 (0.56–3.72), p=0.451.52 (0.60–3.83), p=0.37
C. difficile
Control9/166 (5.4%)4/166 (2.4%)....
Intervention8/192 (4.2%)1/192 (0.52%)0.28 (0.03–2.95), p=0.290.26 (0.03–2.59), p=0.25
E. coli O157
Control7/166 (4.2%)9/166 (5.4%)....
Intervention9/192 (4.7%)8/192 (4.2%)0.69 (0.14–3.40), p=0.650.59 (0.12–2.93), p=0.52
STEC
Control2/166 (1.2%)7/166 (4.2%)....
Intervention3/192 (1.6%)7/192 (3.6%)0.66 (0.07–6.20), p=0.720.58 (0.07–4.89), p=0.61
Y. enterocolitica
Control0/166 (0.0%)0/166 (0.0%)....
Intervention0/192 (0.0%)1/192 (0.52%)..‡..‡
V. cholerae
Control0/166 (0.0%)0/166 (0.0%)....
Intervention0/192 (0.0%)0/192 (0.0%)..‡..‡
Any Protozoa
Control89/166 (54%)121/166 (73%)....
Intervention109/192 (57%)138/192 (72%)0.93 (0.73–1.19), p=0.560.90 (0.69–1.15), p=0.39
Giardia
Control86/166 (52%)120/166 (72%)
Intervention104/192 (54%)135/192 (70%)0.93 (0.73–1.18), p=0.550.89 (0.69–1.15), p=0.38
Cryptosporidium
Control5/166 (3%)3/166 (1.8%)....
Intervention11/192 (5.7%)4/192 (2.1%)0.57 (0.06–5.38), p=0.620.55 (0.06–4.93), p=0.59
E. histolytica
Control0/166 (0.0%)0/166 (0.0%)....
Intervention2/192 (1%)8/192 (4.2%)..‡..‡
Any virus
Control21/166 (13%)18/166 (11%)....
Intervention30/192 (16%)22/192 (11%)0.86 (0.37–1.97), p=0.720.95 (0.41–2.19), p=0.91
Norovirus GI/GII
Control15/166 (9%)15/166 (9%)....
Intervention26/192 (14%)17/192 (8.8%)0.65 (0.25–1.69), p=0.380.74 (0.28–1.90), p=0.53
Adenovirus 40/41
Control6/166 (3.6%)1/166 (0.6%)
Intervention5/192 (2.6%)5/192 (2.6%)6.12 (0.48–78.34), p=0.166.01 (0.49–73.94), p=0.16
Rotavirus A
Control1/166 (0.6%)2/166 (1.2%)....
Intervention1/192 (0.52%)1/192 (0.52%)..‡..‡
Coinfection,≥2 GPP pathogens
Control89/166 (54%)120/166 (72%)....
Intervention102/192 (53%)132/192 (69%)0.96 (0.77–1.19), p=0.690.95 (0.76–1.19), p=0.67
Trichuris
Control39/95 (41%)62/95 (65%)....
Intervention32/106 (30%)57/106 (54%)1.11 (0.74–1.67), p=0.601.16 (0.77–1.75), p=0.47
Ascaris
Control27/95 (28%)34/95 (36%)
Intervention19/106 (18%)21/106 (20%)0.88 (0.43–1.79), p=0.720.89 (0.44–1.79), p=0.74
Coinfection,≥2 STH
Control18/95 (19%)31/95 (33%)....
Intervention13/106 (12%)16/106 (15%)0.71 (0.30–1.70), p=0.440.72 (0.31–1.69), p=0.46
  1. Analysis includes children with complete observations at baseline and 24-month visits. Prevalence results are presented as (n/N (%)). All effect estimates are presented as prevalence ratios (ratio of ratios) with 95% confidence intervals and estimated using generalized estimating equations to fit Poisson regression models with robust standard errors.

    * Pathogen outcomes adjusted for child age and sex, caregiver’s education, and household wealth index, reported diarrhea also adjusted for baseline presence of a drop-hole cover and reported use of a tap on compound grounds as primary drinking water source.

  2. † Models would not converge due to sparse data.

Appendix 1—table 16
Outcome and covariate descriptions, coding, and % missing.
Baseline, n = 98712 month, n = 93924 month, n = 1001
% missing% missing% missingVariable descriptionData source
Outcome Data
Enteric infection outcome data available24148.0Binary; 0/1Based on collection of stool material and successful analysis by GPP
STH infection outcome data available303746Binary; 0/1Based on collection of stool material and successful analysis by Kato-Katz
Caregiver-reported diarrhea, 7-day recall1.37.820Binary; 0/1Child Survey
Covariate data
Child sex, female2.31.37.0Binary; 0=male, 1=femaleChild Survey
Respondent is child's mother2.57.620Binary; 0/1Child Survey
Caregiver completed primary school0.81.76.7Binary; 0/1Child Survey
Child breast feeds with or without complementary feeding1.37.720Binary; 0/1Child Survey
Child exclusively breastfeeds1.37.720Binary; 0/1Child Survey
Child wears a diaper1.47.620Binary; 0/1Child Survey
Child feces is disposed of in a latrine1.37.120Binary; 0/1Created from survey questions in Child Survey
Child age at sampling, days231617IntegerCreated from birthdate (Child Survey) and date of sampling
Child age at survey, days2.67.519IntegerCreated from birthdate (Child Survey) and date of Survey
30-day cumulative rainfall at sampling211410ContinuousCreated from sample date and data from data from the National Oceanic and Atmospheric Administration’s National Centers for Environmental Information (https://www.ncdc.noaa. gov/cdo-web/datatools/findstation)
30-day cumulative rainfall at survey1.37.119ContinuousCreated from survey date and data from data from the National Oceanic and Atmospheric Administration’s National Centers for Environmental Information (https://www.ncdc.noaa. gov/cdo-web/datatools/findstation)
Sample collection during rainy season211410Binary; 0/1Created from sample date. Rainy season defined as November – April.
Survey collection during rainy season1.37.119Binary; 0/1Created from survey date. Rainy season defined as November – April.
Household crowding, >3 persons/room0.40.32.7Binary; 0/1Created from questions in Household Survey
Household floor is covered0.40.32.7Binary; 0/1Observation
Household walls made of concrete, bricks or similar0.40.32.7Binary; 0/1Observation
Household population0.30.31.6IntegerHousehold survey
Number of rooms in household0.40.32.3IntegerCreated from questions in Household Survey
Wealth score, 0 (poorest) - 1 (wealthiest), unitless0.40.32.7ContinuousCreated from questions in Household Survey using Simple Poverty Scorecard for Mozambique (http://www.simplepovertyscorecard.com/MOZ_2008_ENG.pdf). Questions referencing latrine removed from 12 month and 24 month score. All scores normalized by total number of points available.
Household uses tap in compound as primary drinking water source1.71.02.0Binary 0/1Created from drinking water source question in Household Survey
Latrine has drop-hole cover1.90.00.0Binary; 0/1Observation
Latrine has a ventpipe1.80.00.0Binary; 0/1Observation
Latrine has a ceramic, tile, or concrete pedestal or slab2.20.10.1Binary; 0/1Observation
Latrine has sturdy walls made of concrete, bricks, or similar1.90.00.0Binary; 0/1Observation
Compound population0.00.00.0IntegerCompound Survey, enrollment checklists
Number of households in compound0.00.00.0IntegerCompound Survey, enrollment checklists
Number of latrines present in the compound0.10.00.0IntegerCompound Survey
Persons per latrine1.80.10.3ContinuousCreated by dividing the compound population by the number of latrines/drop-holes
Households per latrine1.80.10.3ContinuousCreated by dividing the number of households in the compound by the number of latrines in the compound
Number of water taps present in the compound1.10.00.0IntegerCompound Survey
Standing water visible around compound grounds1.90.30.0Binary; 0/1Observation
Standing or leaking wastewater visible around compound grounds1.90.30.0Binary; 0/1Observation
Faeces or used diapers observed around compound grounds or in solid waste1.90.30.0Binary; 0/1Observation
Compound floods when it rains0.00.00.0Binary; 0/1Compound Survey
Compound has electricity that normally functions0.00.00.0Binary; 0/1Compound Survey
Compound-level population density2.21.51.5Continuous, persons/m2Created by dividing the population of the compound by the measured area of the compound
Any animal present in the compound0.00.40.0Binary; 0/1Observation
Dog(s) present in the compound0.00.40.0Binary; 0/1Observation
Chicken(s) and/or duck(s) present in the compound0.00.40.0Binary; 0/1Observation
Cat(s) present in the compound0.00.40.0Binary; 0/1Observation
Any other animal(s) present in the compound0.00.40.0Binary; 0/1Observation
Appendix 1—figure 5
Schematic of communal sanitation block design from the NGO (Water and Sanitation for the Urban Poor).

Pictured: two latrine stalls, two pour-flush toilets, septic tank, elevated water storage tank, laundry basin, door. Not pictured: soakaway pit. Source: Water and Sanitation for the Urban Poor.

Appendix 1—figure 6
Construction of a soakaway pit for discharge of liquid effluent from intervention latrines.
Appendix 1—figure 7
Photo of communal sanitation block as constructed.
Appendix 1—figure 8
Photo of shared latrine as constructed.
Appendix 1—figure 9
Map illustrating locations of intervention (n=208) and control sites (n=287) compounds.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files and code have been provided for all analyses and specifically for Figure 1 and Tables 1, 2, and 3. Additionally, we have archived all data and code at Open Science Framework (https://osf.io/me2tx, DOI 17605/OSF.IO/ME2TX).

The following data sets were generated
    1. Brown J
    (2020) Open Science Framework
    ID me2tx. Effects of an urban sanitation intervention on childhood enteric infection and diarrhoea in Mozambique.

References

  1. Software
    1. Satterthwaite D
    2. Beard VA
    3. Mitlin D
    4. Du J
    (2019) Untreated and unsafe: Solving the Urban Sanitation Crisis in the Global South Solving the Urban Sanitation Crisis in the Global South Untreated and Unsafe
    Untreated and unsafe: Solving the Urban Sanitation Crisis in the Global South Solving the Urban Sanitation Crisis in the Global South Untreated and Unsafe.
  2. Book
    1. UNICEF/WHO
    (2019)
    Progress on Household Drinking Water, Sanitation and Hygiene 2000-2017
    Special focus on inequalities.

Article and author information

Author details

  1. Jackie Knee

    1. London School of Hygiene & Tropical Medicine, Faculty of Infectious Tropical Diseases, Disease Control Department, London, United Kingdom
    2. Georgia Institute of Technology, School of Civil and Environmental Engineering, Atlanta, United States
    Contribution
    Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0834-8488
  2. Trent Sumner

    Georgia Institute of Technology, School of Civil and Environmental Engineering, Atlanta, United States
    Contribution
    Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  3. Zaida Adriano

    WE Consult ltd, Maputo, Mozambique
    Contribution
    Investigation, Methodology, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  4. Claire Anderson

    Georgia Institute of Technology, School of Civil and Environmental Engineering, Atlanta, United States
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  5. Farran Bush

    Georgia Institute of Technology, School of Chemical and Biomolecular Engineering, Atlanta, United States
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  6. Drew Capone

    1. Georgia Institute of Technology, School of Civil and Environmental Engineering, Atlanta, United States
    2. University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, United States
    Contribution
    Investigation, Methodology, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2138-6382
  7. Veronica Casmo

    Instituto Nacional de Saúde, Maputo, Mozambique
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  8. David Holcomb

    1. University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, United States
    2. University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Environmental Sciences and Engineering, Chapel Hill, United States
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4055-7164
  9. Pete Kolsky

    University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, United States
    Contribution
    Conceptualization, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  10. Amy MacDougall

    London School of Hygiene & Tropical Medicine, Faculty of Epidemiology and Population Health, Department of Medical Statistics, London, United Kingdom
    Contribution
    Formal analysis, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
  11. Evgeniya Molotkova

    Georgia Institute of Technology, School of Biological Sciences, Atlanta, United States
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  12. Judite Monteiro Braga

    Instituto Nacional de Saúde, Maputo, Mozambique
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  13. Celina Russo

    Georgia Institute of Technology, School of Civil and Environmental Engineering, Atlanta, United States
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  14. Wolf Peter Schmidt

    London School of Hygiene & Tropical Medicine, Faculty of Infectious Tropical Diseases, Disease Control Department, London, United Kingdom
    Contribution
    Conceptualization, Formal analysis, Methodology, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  15. Jill Stewart

    University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, United States
    Contribution
    Methodology, Project administration, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3474-5233
  16. Winnie Zambrana

    Georgia Institute of Technology, School of Civil and Environmental Engineering, Atlanta, United States
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  17. Valentina Zuin

    Yale-NUS College, Division of Social Science, Singapore, Singapore
    Contribution
    Conceptualization, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
  18. Rassul Nalá

    Instituto Nacional de Saúde, Maputo, Mozambique
    Contribution
    Conceptualization, Data curation, Project administration, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
  19. Oliver Cumming

    London School of Hygiene & Tropical Medicine, Faculty of Infectious Tropical Diseases, Disease Control Department, London, United Kingdom
    Contribution
    Conceptualization, Supervision, Funding acquisition, Methodology, Project administration, Writing - review and editing
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5074-8709
  20. Joe Brown

    1. Georgia Institute of Technology, School of Civil and Environmental Engineering, Atlanta, United States
    2. University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, United States
    Contribution
    Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing - review and editing
    For correspondence
    joebrown@unc.edu
    Competing interests
    As we have indicated on the ICMJE COI form, attached, this authors's time working on this study was funded in part by the study's funders, the United States Agency for International Development and the Bill and Melinda Gates Foundation.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5200-4148

Funding

Bill and Melinda Gates Foundation (OPP1137224)

  • Oliver Cumming
  • Joe Brown

United States Agency for International Development (GHS-A-00-09-00015-00)

  • Oliver Cumming
  • Joe Brown

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We gratefully acknowledge data collection services and other support provided by the WE Consult team and in particular Wouter Rhebergen and Ellen de Bruijn, and the hard work of the enumerators Isabel Maninha Chiquele, Sérgio Adriano Macumbe, Carolina Zavale, Maria Celina Macuacua, Guilherme Zimba, and Anabela Mondlane. Olimpio Zavale coordinated logistics for early field work. We thank staff at the Instituto Nacional de Saúde, specifically Josina Mate, Acacio Sabonete, and Jeronimo Langa, for their support throughout the project. The study would not have been possible without our implementing partners at Water and Sanitation for the Urban Poor (WSUP), in particular Guy Norman, Carla Costa, Vasco Parente, and Jonathan Stokes. At the Georgia Institute of Technology, we gratefully acknowledge the project and laboratory support provided by Aaron Bivins, Kevin Zhu, David Berendes, Fred Goddard, Olivia Ginn, Sarah Lowry, Olivia Stehr, Haley Lewis, Jonathan Pennie, Derek Whaler, Mio Unno, Catherine Reynolds, Joel Seibel, Diana Chumak, Felicitas Schneider, Katherine Brand, Jiaxin Li, and Meredith Lockwood. We also thank Ben Arnold, Jack Colford, Radu Ban, Jay Graham, Tony Kolb, Eddy Perez, Jan Willem Rosenboom, Tom Slaymaker, Larry Moulton, and Darren Saywell for technical and study design input. We recognize the early contributions of the late Dr. Jeroen Ensink to the MapSan trial protocol. As a colleague, and as a friend, he is sorely missed. Finally, we acknowledge and thank all of the participants and their families who graciously welcomed us into their homes and were so generous with their time.

Ethics

Clinical trial registration ClinicalTrials.gov, number NCT02362932.

Human subjects: The study protocol was approved by the Comité Nacional de Bioética para a Saúde (CNBS), Ministério da Saúde (333/CNBS/14), the Research Ethics Committee of the London School of Hygiene & Tropical Medicine (reference # 8345), and the Institutional Review Board of the Georgia Institute of Technology (protocol # H15160).

Copyright

© 2021, Knee et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,484
    views
  • 332
    downloads
  • 43
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jackie Knee
  2. Trent Sumner
  3. Zaida Adriano
  4. Claire Anderson
  5. Farran Bush
  6. Drew Capone
  7. Veronica Casmo
  8. David Holcomb
  9. Pete Kolsky
  10. Amy MacDougall
  11. Evgeniya Molotkova
  12. Judite Monteiro Braga
  13. Celina Russo
  14. Wolf Peter Schmidt
  15. Jill Stewart
  16. Winnie Zambrana
  17. Valentina Zuin
  18. Rassul Nalá
  19. Oliver Cumming
  20. Joe Brown
(2021)
Effects of an urban sanitation intervention on childhood enteric infection and diarrhea in Maputo, Mozambique: A controlled before-and-after trial
eLife 10:e62278.
https://doi.org/10.7554/eLife.62278

Share this article

https://doi.org/10.7554/eLife.62278

Further reading

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Amanda C Perofsky, John Huddleston ... Cécile Viboud
    Research Article

    Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the contribution of this process to variability in annual epidemics is not well understood. Here, we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the United States during 1997—2019. We integrate phenotypic measures of HA antigenic drift and sequence-based measures of HA and NA fitness to infer antigenic and genetic distances between viruses circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology. Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics, higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults relative to children, consistent with increased population susceptibility. Based on random forest models, A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that subtype interference is a major driver of influenza A virus infection ynamics, presumably via heterosubtypic cross-immunity.

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Rashmi Sukumaran, Achuthsankar S Nair, Moinak Banerjee
    Research Article

    Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and Genome-wide association studies (GWAS) risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation, and proportion analysis, signifies ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high systolic blood pressure in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population-specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic-specific variation can help in determining regional risk drivers for stroke. Unique ethnic-specific risk variants and their distinct patterns of linkage disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population- and comorbidity-specific risk variants might help in defining the threshold for risk, and aid in developing population-specific prevention strategies for stroke.